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Summary 
 
The introduction of shape as a design parameter for particulate carrier systems shows 
promising potential to improve drug and gene delivery. In order to optimize current 
therapeutic strategies, various new particle geometries were proposed to adapt to specific 
hurdles of application routes and to modify interactions within biological environments. For 
the transport of active agents into the respiratory tract, elongated, aspherical particles were 
shown to reach the alveolar region and additionally offering the modification of the clearance 
rate by alveolar macrophages.  
In the presented work a template-assisted particle engineering technique was used to fabricate 
elongated, cylindrical microparticles of defined diameter and length. Therefore, nanoparticles 
were interconnected with each other within shape defining pores of a template membrane 
building up a micron structure. Designed as a gene delivery system, plasmid DNA and a 
lysosomal buffering agent were applied as a functional polymer coating, which at the same 
time provided the stabilization of the system. The resulting microparticles were shown to be 
qualified for pulmonary administration featuring aerodynamic properties to reach the deep 
lung. In addition, particle geometry was adjusted to provide high uptake rates into alveolar 
macrophages as the target cells while showing no cytotoxicity. A successful implementation 
of the transported gene into the phagocytes could be shown in cell culture studies on MH-S 
cells (murine alveolar macrophages). The transfection provided by the carrier system was also 
successfully translated into a mouse lung model (BALB/c) qualifying the presented 
microparticles for the targeted gene delivery to alveolar macrophages. 
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Kurzzusammenfassung 
 
Die Formgebung von partikulären Trägersystemen birgt großes Potential für die Verbesserung 
der Pharmako- und Gentherapie. Um den spezifischen Ansprüchen verschiedener 
Applikationen gerecht zu werden, wurde bereits eine Vielzahl unterschiedlicher Formen 
eingeführt, insbesondere mit der Absicht den Transport der Wirkstoffe zu verbessern und 
Interaktionen mit dem Organismus zu modifizieren. Speziell für den effizienten Transport von 
Therapeutika in die Lunge konnten asphärische Partikel als vorteilhaft identifiziert werden. 
Zusätzlich konnte für diese Partikelart gezeigt werden, dass die Aufnahme durch 
Makrophagen gezielt verbessert oder auch verlangsamt werden kann. In der vorliegenden 
Arbeit wurde eine Template-gestützte Methode für die Herstellung von asphärischen, 
zylindrisch geformten Mikropartikeln angewendet. Die Methode erlaubte dabei die exakte 
Einstellung des Durchmessers und der Länge der Partikel. Dafür wurden kleinere 
Nanopartikel innerhalb einer formgebenden Matrize miteinander verbunden, indem eine 
Beschichtung mit Polymeren erfolgte. Die hierfür verwendeten Substanzen waren eine 
Plasmid-DNA und ein Stickstoffpolymer mit hoher Pufferkapazität, um die Partikel als 
Gentransportsystem einzusetzen. Die erhaltenen Mikropartikel wurden erfolgreich auf ihre 
Lungengängigkeit geprüft und ermöglichen eine hohe Aufnahme in Alveolarmakrophagen. 
Toxische Effekte konnten für die Partikel nicht beobachtet werden. In Zellkultur-
Experimenten an Alveolarmakrophagen der Maus konnte gezeigt werden, dass die Partikel 
eine Einschleusung des transportierten Gens in den Kern der Zellen bewerkstelligen können. 
Zusätzlich konnte auch im lebenden Tier (BALB/c Mäuse) eine Expression des Gens gezeigt 
werden, was die präsentierten Mikropartikel zu einem geeigneten Kandidaten für die 
Gentherapie in der Lunge macht. 
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I.1 Principles of Pulmonary Delivery 
 
In pharmacotherapy the lung is a very prominent compartment of the human body. Offering a 
non-invasive route of administration, pulmonary drug delivery in theory can be used for both 
local and systemic treatment. For the latter, the high surface area of up to 150 m² in 
combination with a distinct vascularization indicates the lung to be a suitable target for 
delivery approaches.[1] Additionally, the air-blood barrier is a very thin epithelial layer 
featuring a minimum thickness of only 0.1 µm.[2] This consequentially facilitates air exchange 
in the alveoli, but also the introduction of drugs into the blood stream. However, up to now 
there is no successful market product available using this particular application route.[3]  
In contrast to that, the local delivery of therapeutic agents into the respiratory tract is the 
recommended strategy for treating inflammatory disorders such as chronic obstructive 
pulmonary disease (COPD), asthma or pulmonary fibrosis.[4] Therefore, active pharmaceutical 
ingredients (APIs) such as glucocorticoids or β2-sympathomimetic drugs are aerosolized for 
inhalation to mitigate the common symptoms of patients. For aerosolization, three different 
principles can be distinguished. Metered dose inhalers (MDI) use propellants that are 
liquefied under pressure.[5] The drug is suspended or dissolved in the propellant, which 
evaporates upon activation of the inhaler. A single metered dose is released as API-containing 
droplets to reach the respiratory tract following the inhalation stream. By using vaporizers 
aqueous drug solutions can be applied, which are nebulized into a fine mist. Here, the droplets 
are generated e.g. by oscillations provided by a piezo crystal, which are transferred to the drug 
solution.[6] As a third option for aerosolization, dry powder inhalers (DPI) can be used. 
Therefore, solid drug substance particles, that can be associated to a carrier to prevent the 
formation of larger agglomerates, are inhaled.[7] In order to reach an effective deposition of 
the droplets or solid particles within the pulmonary system, specific parameters have to be 
considered for the formulation. The size of the droplets or particles is of major impact 
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determining the site of action for the active agent. As presented in Figure 1, for large particles 
exceeding the size of 5 microns, high impaction rates in the upper airways can be expected.[8] 
Here, they can cause the common local side effects during treatment. The optimum size is 
reported to be in the range from 1 to 5 µm leading to sedimentation und diffusion into the 
deeper compartments of the lung.[8, 9] Regarding very fine aerosols featuring sizes below 
0.5 µm the majority of the formulation is expected to be exhaled after application.[10-12]  
         
 
 
 
However, as presented in Figure 2, a second maximum for the deposition can be observed for 
particles in the low nanometer scale.[13] In this study an efficiency of up to 50 % was found for 
the alveolar region regarding nanoparticles in the range of 10 nm. An additional aspect, which 
highly influences particle deposition patterns, is particle density.[14] The group of Robert 
Langer at MIT published a study on large porous particles made of insulin and testosterone.[14] 
They produced particle diameters of up to 20 µm, which usually show high impaction in the 
upper lung. But at the same time the density of the particles was reduced enabling high 
deposition and therefore bioavailability of the delivered drugs. They impressively emphasized  
Figure 1: Aerosol deposition within the respiratory tract in dependence on particle size. [8] 
Whereas larger particles show impaction in the upper airways, particles in the size range of 
1-5 microns reach the deep lung.[9]   
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density as a crucial parameter for the aerodynamic behavior of airborne particles. Both size 
and density are expressed in the aerodynamic diameter d(aer) (Equation 1), which is a 
prominent parameter for aerosol characterization. It provides information about the 
accessibility of an aerosolized particle formulation for the pulmonary system as an important 
quality attribute. Described in both the US and European pharmacopeias, d(aer) can be 
assessed by cascade impactor testing.[15] 
 
𝑑(𝑎𝑒𝑟) =  𝑑(𝑔𝑒𝑜)√𝜌 
 
 
In Figure 3, as an example the most commonly used Andersen impactor is depicted. After 
aerosolization the formulation follows the undertow of the vacuum and enters the impactor. A 
Figure 2: Particle deposition efficiency in dependence on 
region and particle size.[13] 
Equation 1: The aerodynamic diameter d(aer) expressed 
as a function of the geometric diameter d(geo) of the 
particle and its density 𝜌. 
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first selection of particle sizes can be conducted by a preseparator, which prevents particles 
larger than 10 µm from entering the setup as correspondingly they would not enter the deep 
lung. In the next step heterogeneous particle populations of the formulation will be sized by 
inertia. This means whenever a particle is not able to follow the undertow anymore, it impacts 
in the respective stage allowing a separation of defined particle d(aer) ranges. For the 
Andersen impactor the aerosol stream passes 8 particle collection stages. At stage 0 particles 
of 9.0 microns and larger impact whereas stage 7 forces 0.4 to 0.7 µm particles to deposit onto 
the collection plates. Mentioned as apparatus E in the European pharmacopeia, a new 
impactor design is listed based on a horizontal cascade setup.[15] Commercialized as New 
Generation Impactor (NGI) the device was developed by the pharmaceutical industry for 
facilitated high-throughput testing. Featuring high accuracy and reproducibility, the new  
 
      
 
 
Figure 3: Schematic overview of an Andersen cascade impactor including a vacuum setup for 
aerosolization.[12]   
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design meets all pharmacopeia specifications. For the presented work, the NGI was used for 
the determination of the aerodynamic properties of the fabricated delivery system. Hence, a 
detailed description with a focus on the metrics which can be calculated from an NGI run is 
presented in chapter IV. Besides size and density a third particle design parameter, even 
though still under-represented in recent publications, is shape. On the one hand shape 
modifications can be exploited for improved delivery results, but on the other hand shape is a 
relevant parameter for biological interactions after reaching the desired target compartment. 
For pulmonary delivery only few studies are available, however, results indicated a beneficial 
behavior of elongated, fiber-like particles, which is outlined in the following section. Here, 
examples of non-spherical shapes in drug delivery are presented focusing on advancements 
for pulmonary carrier systems.     
I.2 Aspherical Particles in Pulmonary Drug Delivery 
 
In recent years, shape as a design parameter for particulate drug delivery systems gained 
increasing attention. The encapsulation of active agents into polymeric carrier systems adds 
beneficial features regarding API protection, release profiles or facilitated application.[16] In 
this regard, a lot of emphasis was put on chemistry and surface modifications to create 
biocompatible systems enabling a targeted delivery and controlled release of the transported 
cargo. In addition to that, shape was identified as an important and relevant parameter e.g. to 
modify interactions within biological environments or to improve delivery for specific 
administration routes.[17]  As presented in Figure 4, many novel shapes were introduced, 
which clearly differ from the regular spherical systems. Therefore, scientists used a wide 
range of different fabrication techniques. Xu and colleagues published a work on the 
production of rod-like shaped particles (Figure 4 D).[18] They applied a microfluidic device  
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providing full control on the shape of the resulting particles. However, their experimental 
setup was limited to the production of rod sizes from 20 to 100 µm, which is not convenient 
for many administration routes such as pulmonary application. However, for suitable sizes the 
elongated structure of rod- or fiber-like carrier systems has been evaluated for the transport 
into the respiratory tract. Su et al. published a study on fibers and spherical particles 
comparing their efficiency to reach the peripheral lung.[19] They could demonstrate fibers to 
have a higher probability to deposit in the desired pulmonary region, whereas spheres 
featuring the same aerodynamic diameter are held back in the oral and nasal region. This was 
supported by a mathematical approach carried out by Sturm and colleagues.[20] They again 
stated improved chances of fibers for deep lung deposition. In this context, aspect ratio (AR), 
Figure 4: Overview of various aspherical shapes of 
particle systems. Different methods were applied for the 
fabrication of plug-shaped (A), torroidal (B), vase- or rod-
shaped (C, D) particles. Even perfectly curved or conical 
shapes could be presented (E, F).[17] 
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the quotient of length to diameter of the particle system, is a crucial parameter. By adjusting 
AR, particle deposition patterns can be estimated, which indicates the possibility of a site 
specific transport into the lung.[19] In addition to potentially improved pulmonary delivery 
aspects, rod-like shaped particles provide the possibility to alter cellular interactions. Upon 
aerosolization and deposition within the respiratory tract, spherical microparticles can be 
efficiently engulfed by phagocytes, e.g. alveolar macrophages, and cleared from the target 
site. This leads to the removal of the active agents and therefore a reduced therapeutic 
outcome. In this regard, Champion and Mitragotri demonstrated the invagination of carrier 
systems by phagocytes to be drastically dependent on their shape.[21] High aspect ratios can be 
utilized to delay uptake into macrophages.[22] This can prolong the residence time of APIs 
resulting in higher bioavailability and as a result superior therapeutic performance of the 
carrier. Besides decreased phagocyte interactions for uptake retardation, rod-like particles can 
also be designed to act as an agent for cell surface functionalization. The group of Michael 
Rubner at MIT presented a study on the fabrication of polymer rods, which act as a “cellular 
backpack” for macrophages.[23] In order to leverage the native functions of the cells, they 
again exploited the rod-like shape to create phagocytosis-resistant particles. By picking 
suitable polymers such as chitosan, they were able to immobilize the particles on the cell 
membrane (Figure 5). As a carrier system for diagnostic and therapeutic agents, the rods are 
reported to be qualified for targeted delivery without hampering proliferation or viability of 
the cells. For the fabrication of the particles, they applied a template-assisted approach 
depicted in Figure 6. A polycarbonate membrane was coated by different polymers, which 
cover the whole surface of the membrane including the inner surface of the pores. By plasma 
etching, they had to selectively remove the polymer film from the surface, whereas the 
coating within the pores was maintained. After sufficient polymer deposition the template was 
dissolved in an organic solvent to harvest the particles. A similar engineering technique for 
the production of rod-like shaped particles was introduced by our group.[24] Here, Kohler and  
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colleagues created rod- or fiber-like shapes by the interconnection of nanoparticles. Based on 
a bottom-up engineering approach, nanomaterial built up micron structures within the pores of 
Figure 5: Rod-like shaped polymer particles 
(red) acting as cellular backpack on mouse 
macrophages; scale bar 10 µm.[23] 
Figure 6: Template-assisted production of hollow, rod-like shaped microparticles. The template 
membrane gets coated with different polymers, which are released by membrane dissolution.[23]  
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a template membrane. According to the geometry of the pores, the resulting particles featured 
an elongated, cylindrical shape. Using this method, it was possible to connect single 
nanoparticles to a chain applying a polymer coating (Figure 7). By changing the pore 
diameter of the template, AR can be easily adjusted for the particles. In contrast to uptake 
retardation, specific ARs are reportedly engulfed to a higher extent than comparable 
spheres.[21] This indicates the possibility of targeted delivery to phagocytes and shows rod-like 
shaped particles to be a versatile tool box to modify interactions at the micro-bio interface.  
In general, shape is a promising new design parameter within particle engineering, which 
should always be considered to optimize delivery efficiencies. For the presented thesis, the 
method by Kohler et al. was applied for the fabrication of particles achieving a macrophage 
targeting followed by high uptake rates. The further development and the transition into a 
delivery system for DNA will be carried out in detail in chapter II. 
  
 
 
 
 
       
 
 
 
Figure 7: Template-assisted connection of single nanoparticles into a chain 
structure.[24] 
 - 13 - 
 
I.3 Layer-by-Layer Coating Technique 
 
The Layer-by-Layer (LbL) coating technique was for the first time described by Gero Decher 
in 1991 on planar surfaces.[25] Based on the assembly of mainly polymeric materials, 
electrostatic, but also hydrophobic forces and H-bonds can be exploited to provide the 
deposition of thin films onto almost any kind of substrate.[26, 27] The basic coating procedure is 
shown in Figure 8 utilizing opposite charges of two polyelectrolytes for attachment.[25] As the 
substrate shows positive surface charges, polyanions can be used to start the coating 
procedure. The initial surface charges get overcompensated by the polymeric material 
allowing the deposition of polycations in a second step. In between the coating steps, 
additional washing steps are used to get rid of excess polymer. Since the introduction of the 
technique, the number of applied excipients was constantly increased to challenge its potential 
within the fields of material or biomedical sciences. The method provides the deposition of 
                                   
 
 
 
 nanometer-thin polymer layers offering the freedom to incorporate a broad range of 
functional components to create new materials according to the desired application 
Figure 8: Schematic illustration of LbL polymer deposition of 
polyelectrolytes onto a planar substrate.[22]  
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purpose.[28] In Figure 9, the transmission electron microscopy (TEM) visualization of an LbL 
meshwork cross-section is shown, illustrating the subsequent coating of different polymers.[29] 
The composition of the layers can be changed by the operator as desired to control the 
position and total amount of the applied compounds. Regarding biomedical applications, LbL 
coating procedures can provide the deposition of active agents into polymeric matrices for 
modified release profiles and targeting purposes while preserving their therapeutic activity.[30-
32] Both synthetic and natural polymers, such as therapeutic proteins or nucleic acids, can be 
applied. The fabricated films are applicable to medical devices like stents and tissue 
engineering implants or colloidal drug delivery systems.[33-36] Reibetanz et al. published a  
 
 
 
 
 
work on the LbL assembly of plasmid DNA encoding for green fluorescent protein (GFP) in 
combination with protamine.[37] As a substrate, they applied colloidal silica particles of 3 µm 
in size. After preparation, the multi-layered particles were applied to HEK 293T cells as 
presented in Figure 10. Due to the red fluorescence label of protamine, they could confirm 
the uptake of the particles into the cytosol of the cells. In addition, the cells expressed GFP 
Figure 9: TEM image of an LbL meshwork built up by polyallylamine hydrochloride (PAH), 
polyacrylic acid (PAA), sulfonated polystyrene (SPS) and silver nanoparticles (Ag). The layers are 
coated onto a polystyrene (PS) substrate.[29]  
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indicating a successful delivery of the plasmid DNA into the nuclear core of the target cells. 
Here, the LbL meshwork was on the one hand able to provide protection of the incorporated 
active agent from degrading cellular enzymes. On the other hand the intracellular release was 
sufficient for transgene expression qualifying the presented LbL-based system for the 
introduction of genes into HEK 293T cells. In order to optimize the efficiency of LbL-
promoted gene delivery, different strategies were introduced e.g. focusing stimuli-responsive 
behavior. Blacklock et al. published a work on the fabrication of multilayered films using 
DNA and a cationic peptide featuring disulfide bonds.[38] Whereas the peptide is stable under 
non-reducing conditions, the bonds are cleaved within a suitable reductive environment. 
                             
 
 
 
As a consequence, the LbL meshwork gets destabilized for a triggered cargo release (Figure 
11 A). Another strategy is based on materials, which can be cleaved within an enzymatic 
environment (11 B).[39] Utilizing degrading enzymes for triggered release is in particular a 
promising approach for intracellular cargo delivery taking into account the enzymatic arsenal 
Figure 10: Fluorescence micrograph of LbL coated and labeled 
silica microparticles (red) into HEK 239T cells. Cells appear in 
green due to expressed GFP.[37]   
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present in endo- and phagolysomomes of the target cells.[41] In summary, the introduction of 
LbL coating techniques into drug and gene delivery adds a versatile tool to the controlled 
delivery of therapeutic agents. The method is very robust to excipient changes offering the 
possibility of customized film designs, which can be optimized to the needs of specific 
applications. The technique especially benefits from progress in polymer chemistry and 
material sciences indicating LbL coating techniques to be a promising platform technology 
for advanced surface functionalization.  
 
                           
                                                            
 
 
 
 
Figure 11: Stimuli-responsive LbL designs for triggered cargo 
release due to polymer reduction (A) or enzymatic degradation 
(B).[35, 36] 
A 
B 
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I.4 Macrophage Engineering 
 
Macrophages are part of the innate immune system and play a pivotal role in a large number 
of immunological cascades. In their role as scavenger cells, they stand sentinel to pathogen 
exposure in all tissues and at important body barriers as presented in Figure 12.[41] In this 
regard, they present initially processed pathogens to T-lymphocytes and act as cytokine 
secreting cells.[42, 43] Thereby, macrophages mediate, but also regulate immune-based 
inflammatory conditions. Due to their important role in immunological responses, an altered 
activity or dysfunction of macrophages can have crucial impact on the development and 
exacerbation of various diseases. Macrophage participation is frequently discussed for many 
pathological conditions including cancer and chronic inflammatory disorders.[44] Recently  
 
                       
 
 
Figure 12: Overview of macrophage presence throughout the human body. 
All important biological barriers such as the intestines, the blood-brain barrier 
or the lung are settled with macrophages.[37] 
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focused by many working groups, the involvement of macrophages in malignant diseases is a 
very prominent research topic. Tumor-associated macrophages (TAMs) play a major role in 
the development of carcinoma potentially promoting cellular remodeling and proliferation, 
neovascularization and metastasis.[45] Therefore, TAMs highly express and secret growth 
factors as well as cytokines defining a microenvironment that is directly involved in tumor 
progression.[46] Regarding lung carcinoma, high density of infiltrating macrophages has been 
correlated with poor clinical outcomes.[47] This is due to alveolar macrophages secreting e.g. 
vascular epidermal growth factor (VEGF), which is expected to contribute to increased tumor 
angiogenesis.[43] In addition to malignant diseases, macrophage participation is also discussed 
for many different inflammatory disorders. Keeping the focus onto the lung, pulmonary 
fibrosis and chronic obstructive pulmonary disease (COPD) are expected to be promoted and 
worsened by overly active pro-inflammatory macrophages.[48] Within these conditions, they 
secret cytokines such as TNF-α at high levels, which is a key player in chronic 
inflammation.[49]  
Both malignant and chronic inflammatory diseases are up to the present day only 
insufficiently treatable demanding novel therapeutic strategies. Therefore, gene therapy can 
be a powerful tool promoting access to the relevant genes by highly specific transfection 
systems. In order to modify mediator secretion on DNA level, many techniques were 
developed for the genetic engineering of target cells. Both vectors or non-viral, polymer-
based delivery systems for the introduction of pDNA, siRNA or mRNA were introduced.[50-52] 
In the context of inflammatory disorders of the respiratory system, Kelly and colleagues 
presented a microparticulate delivery system, which they showed to be effective in 
introducing siRNA into alveolar macrophages.[53] Optimizing the carrier to be biodegradable 
and qualified for pulmonary administration, the delivered cargo selectively knocked down 
TNF-α expression in a cell culture model. The study is one example among many others, 
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which contributes to the progression and further development of gene therapy towards the 
translation into clinical applications. Very recently, CRISPR/Cas9 tools again provided the 
spirit of optimism within the scientific community, showing promising potential and receiving 
the approval for human clinical trials in June, 2016.[54] In this regard, novel transfection tools 
concurrently increase the demand for equally advanced delivery systems to overcome the 
specific hurdles of cellular targets and specific application routes defining the scope of the 
presented thesis. 
 
I.5 Aim of the Work 
 
The presented work is characterized by its strong interdisciplinarity combining aspects of 
pharmaceutical technology, biopharmacy, gene delivery and cell biology. A novel particulate 
carrier system of aspherical shape is in the focus merging delivery into the respiratory system 
with the introduction of a model gene into a target cell line.  
In this regard, a novel particle engineering method, initially developed by our group, was 
adapted and extended to the requirements of a gene delivery approach. Prior studies explored 
the possibility to fabricate fiber-like or rod-like shaped particles of defined sizes by using 
regular filter membranes. Within the pores of the membranes, nanomaterial can be 
interconnected leading to cylindrical microparticles. The first particles gained from this 
technique did not feature pharmaceutically relevant excipients, such as functional polymers or 
active agents. A general development of the engineering technique and smart excipient 
choices were prioritized in order to stabilize the shape of the carrier. In addition, the 
interaction of the particles with macrophages was evaluated, visualizing the engulfment by 
phagocytosis in much detail.  
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Building on these preliminary studies, the objective of the presented work was the transition 
of the particles into a pulmonary gene delivery system. A targeted delivery of DNA into 
alveolar macrophages was in particular focused, proving the system to be qualified for the 
genetic engineering of phagocytes, a cell species, which is generally considered as hard-to-
transfect. Therefore, a comprehensive physicochemical characterization had to be performed 
including aerodynamic properties after aerosolization. The introduction of a model gene into 
macrophages within biological environments was investigated, both under in vitro and in vivo 
conditions. The work is divided into five scientific chapters displaying the systematic steps of 
the development process:   
 
Chapter II – Template-assisted Production of Aspherical, Nanostructured Microrods Using                  
DNA      
Chapter III – Microrods Featuring Biodegradability 
Chapter IV – Technological Evaluation of Microrods 
Chapter V – Transfection Studies on Murine Alveolar Macrophages  
Chapter VI – Transfection Studies in BALB/c Mice 
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Chapter II  
Template-assisted Production of Aspherical, Nanostructured 
Microparticles Using DNA 
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II.1 Introduction: Microrod Fabrication 
 
For the production of aspherical, nanostructured microparticles a template-assisted method 
was applied. Based on a bottom-up engineering approach, which was previously introduced 
by our group, nanoparticles got infiltrated into the shape-defining pores of a template 
membrane.[1] Followed by the interconnection of the nanomaterial by a polymer coating, the 
aspherical structure was stabilized leading to microparticles representing the cylindrical 
shape of the given template pores.  
Starting the microparticle production with the infiltration of the nanomaterial into the 
membrane, the template (blue membrane, Figure 1 A) was applied to a regular filter holder 
system. Placing a second membrane (orange) underneath, which is referred to as blocking 
membrane and featuring pore sizes far below the nanomaterial size, can guarantee particle 
retention. The nanomaterial was applied by a syringe as an aqueous suspension, which led to 
a piling within the template pores. The water could pass the setup freely providing a 
continuous flow of the suspension through the filter holder system. As presented in 
Figure 1 B the method allows an immediate qualitative feedback about the infiltration result. 
Whereas a turbid nanosuspension is applied to the filter holder system, the suspension water 
leaves the setting as clear filtrate. In a second consecutive step the nanomaterial gets cross-
linked by thin polymer layers. Therefore the template membranes were treated with two 
different polyelectrolyte (PE) solutions within an LbL procedure. The alternating exposure to 
positively (PE+) and negatively (PE-) charged coating agents (Figure 2) led to the 
deposition of thin films on the particles’ surface. As polyanion plasmid DNA was used 
according to the intended gene delivery approach. Providing negative charges from the 
phosphate-sugar backbone, the plasmid can be combined with positively charged polycations 
to build up the coating arranged in double-layers (PE+/PE-). 
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Figure 1: A. Filter holder system hosting the template (blue) and blocking membrane (orange) 
for particle retention. The nanomaterial is applied to the system as an aqueous suspension. 
Whereas the dispersion medium water can pass the setting freely, the particles pile up within the 
template pores as they are not able pass the blocking membrane. Particle length (l) and diameter 
(d) are defined by the geometry of the template pores; B. Syringe-based infiltration of a turbid 
nanosuspension into the filter holder system leading to particle retention in the template pores 
and a clear filtrate. 
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For every successful gene delivery regimen a lysosomal buffering agent is needed besides the 
genetic material.[2-4] The structural characteristics all these excipients share are amino groups, 
which can be protonated under physiological conditions and therefore showing a high 
buffering capacity in biological environments.[5] The positively charged amines can be used as 
the counterpart to the negative plasmid DNA charges to fabricate a functional coating and at 
the same time providing structural integrity for the resulting microparticles. For the presented 
systems, which are exclusively assembled by electrostatic interactions, charge densities of the 
involved polymers determine the stability of the carrier.[6] Therefore polymer and additional 
electrolyte concentrations, coating time and pH values are critical parameters influencing the 
deposition behavior of the polymers.[7, 8] First of all pH values have a strong impact to reach 
high ratios of charged functional groups and are easily modified. By adding additional 
electrolytes to the LbL solutions, polymer deposition can be forced due to the displacement 
from hydration envelopes within defined concentration ranges.[9-11] Especially for template-
engineering techniques the salting-out effect has to be adjusted precisely to avoid excessive 
Figure 2: After the infiltration of the nanomaterial into the template pores, the particles get 
interconnected by a polymer coating. In a Layer-by-layer procedure the templates are applied to 
solutions of cationic and anionic coating agents leading to a cross-linking film and therefore to the 
stabilization of the cylindrical micron structure. 
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coating of the template itself corrupting the release of the particles, which is representing the 
last step of the engineering method. On that front, an example is presented in Figure 11 A in 
this chapter visualizing polymer layers on the template surface as impediment for particle 
release.  
Applied as a sacrificial template, the membrane gets dissolved in an organic solvent to harvest 
the nanostructured microparticles. For this approach, it is vital to use a suitable combination 
of materials and chemicals providing the efficient removal of membrane material while not 
dissolving the functional coating of the carrier system. Using polycarbonate (PC) as 
membrane material combined several advantages for the production method. Showing a 
sufficient degree of flexibility and being tear-proof, the templates can be easily handled 
during the infiltration and coating step. In addition, the range of organic solvents showing 
high solubility for PC such as tetrahydrofurane (THF) or dichloromethane (DCM) does not 
interfere with the LbL coating. After the dissolution of the template, particles can be collected 
by centrifugation and the removal of the polycarbonate in the supernatant. In order to reach 
high yields of microparticles showing the expected uniformity in geometry, the production 
steps were monitored in order to facilitate a rational optimization process. Especially the 
infiltration efficiency of the nanomaterial is regarded as crucial, since insufficiently filled 
pores will consequentially lead to micron structures differing from the template pore shape. 
Therefore, a protocol had to be established providing both the information about the amount 
of nanomaterial needed for one template and about a standard filling procedure making sure 
the pores are filled homogenously. The LbL conditions were adjusted for the stabilization of 
the nanomaterial using DNA with respect to the parameters previously mentioned. In addition 
to that, the alternating nature of the coating procedure could be visualized proving both the 
incorporation of the cargo and the LbL coating progress. Finally, a protocol for the release 
and purification was established separating the microparticles from free nanomaterial and 
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template debris. In the following chapter sections the decisive engineering steps are presented 
leading to a robust and reproducible protocol for the fabrication of aspherical, nanostructured 
microparticles. 
II.2 Monitoring of the Engineering Steps 
 
II.2.1 Infiltration of Nanomaterial into the Templates 
II.2.1.1 Material and Methods 
 
II.2.1.1.1 Material 
As template and blocking membrane track-etched Whatman Nuclepore polycarbonate filter 
membranes (25 mm; pore diameter 3 µm, pore length 10 µm) were used. Placed into Swinnex 
25 mm filter holder systems, the nanosuspension can be applied by a syringe. All components 
of the setting were obtained from Sigma-Aldrich (Taufkirchen, Germany). For infiltration 
spherical silica nanoparticles of 200 nm in size were purchased as aqueous suspension 
(50 mg/mL) from Kisker Biotech (Steinfurt, Germany).  
II.2.1.1.2 Methods 
Template Preparation 
For the following studies, a model nanoparticle made of silica (SNP) was used combining a 
wide range of advantages. Commercially available from numerous manufacturers to 
inexpensive conditions, SNPs are offered at a large size range including surface 
modifications. Especially the availability of different fluorescence labels makes them a 
straight forward candidate concerning tracking and visualization within biopharmaceutical 
and in vitro/ in vivo experiments. Furthermore, SNPs show high efficiency for the presented 
infiltration technique in comparison to organic polymers such as PLGA, which was also 
observed by our group.[12] SNPs are provided exclusively in amorphous state showing density 
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values of 2.2 g/cm³ (PLGA 1.34 g/cm³) potentially leading to a superior sedimentation 
behavior within the template pores. In addition to that, most inorganic nanomaterials show 
high and constant stiffness compared to organic polymers.[13-15] Especially sugar-based 
systems show significant swelling and shrinking when applied to aqueous media and in 
consecutive drying procedures respectively.[16, 17] This implies size changes of the 
nanoparticles during microparticle preparation consequentially leading to variations in length 
and diameter of the desired micron structure. Lastly, indicated by the chemical structure in 
Figure 3, SNPs offer negative surface charges due to terminal oxygen groups providing the 
electrostatic environment needed for the LbL stabilization. For the evaluation of the amount  
                                           
                                                     
 
 
of SNPs needed, the stock suspension was diluted with MilliQ water to a final concentration 
of 1.0 mg/mL. Using aliquots of 500 µL, the diluted nanosuspension got infiltrated into the 
template membranes in multiple steps. After every step, a part of the membrane was cut out, 
dried and prepared for visualization. To determine the rate of sufficiently filled pores, 5 
Figure 3:  Chemical structure of silica (SiO2) 
providing negative surface charges due to anionic 
oxygen groups. 
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random parts of the sample were focused by an electron microscope. For n = 100 pores, the 
number of SNP filled pores were counted.           
Electron Microscopy Visualization 
The membrane cutouts were applied to a carbon disk and sputtered with platinum or gold to a 
layer thickness of 10 nm prior to scanning. An accelerating voltage of 5 or 6 kV with a focal 
distance of 7.5 mm was used. The visualization was performed by a JEOL JSM-7500F 
scanning electron microscope (SEM).  
 
II.2.1.2 Results and Discussion 
In Figure 4 the SEM visualization of a membrane cutout is shown focusing a single pore of 
3 µm in diameter. The picture is taken from the top side of the membrane highlighting 
infiltrated SNPs in a loose packing. Clearly visible, the pore was sufficiently filled and 
therefore regarded as being representative for a positive result during the evaluation of the  
 
 
 
 
 
 
 
 
Figure 4: Electron microscopy (SEM) visualization of SNPs after the 
infiltration into the template membrane. The close-up shows particles of 
200 nm in size piling up within the pore of 3 µm in diameter. 
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filling efficiency. Starting off with the first 500 µL aliquot of the SNP suspension only 44 %                  
of the counted pores were filled sufficiently (Figure 5 A). By adding two consecutive 
infiltration steps, the applied SNP amount was increased to 1.5 mg reaching 83 % of filled 
pores (Figure 5 C). The increase by an additional fourth and fifth step to 85 % and 86 % 
respectively was not regarded as beneficial taking into account the time expenditure of a 
single infiltration.  
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Figure 5: SNP infiltration progress as a triple infiltration step visualized by SEM microscopy. 
Whereas the percentage of filled pores was below 50% for a single filling step (A), the efficiency 
could be increased above 80% after a second (B) and third (C) infiltration summarized in the 
corresponding plot.     
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It seems logical to expect a higher percentage of properly filled pores by providing higher 
amounts of nanomaterial, but SNPs also showed the tendency to mainly deposit in the center 
of the membrane sparing out the pores at the edges. This was due to the filter holder inlet, 
which is placed above the center of the membrane compelling the suspension droplets from 
the syringe into the same area. Initially intended to stepwise determine the right amount of 
SNPs for one template, the multiple filling steps additionally turned out to shift the excessive 
nanomaterial from the inner to the peripheral pores. Since the complete template surface was 
cleansed prior to coating, the loss of nanomaterial could therefore be minimized leading to 
higher yields of microrods. To evaluate this spreading effect, the amount of 1.5 mg SNPs was 
kept constant for the comparison of a single and triple filling step. Illustrated in Figure 6, 
central pores of the template were focused after the infiltration. The excessive nanomaterial 
could be efficiently flushed from the center confirming the multiple infiltration steps to be 
beneficial for homogenously filled templates. To conclude from the first monitoring step, a 
sufficient amount of 1.5 mg of SNP per membrane was determined in addition identifying 
multiple infiltration steps to be beneficial for a homogenous distribution. For all the following 
experiments, the infiltration of the mentioned amount in triplets was maintained. 
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II.2.2 Layer-by-Layer Coating Using DNA 
II.2.2.1 Material and Methods 
 
II.2.2.1.1 Material  
For the production of nanostructured microrods the protocol for the infiltration from the prior 
section was applied using SNPs of 200 nm and templates featuring 3 µm pores. For the LbL 
coating the plasmid DNA pCMV-luc encoding for the reporter gene firefly luciferase was 
obtained from PlasmidFactory (Bielefeld, Germany). For the opposite charges branched 
polyethylenimine (bPEI, MW 25 kDa) was purchased from Sigma Aldrich (Taufkirchen, 
Germany). For agarose gels, agarose NEEO as well as sodium chloride, bromophenol blue-
glycerine mixture, TAE buffer (tris-(hydroxymethyl)-aminomethane (TRIS), sodium acetate, 
ethylenediaminetetraacetic acid (EDTA)) and the intercalating agent ethidium bromide (EtBr) 
were kind gifts from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). 
The visualization was performed by a benchtop Transilluminator UVP (Cambridge, UK). The 
organic solvent THF for the template dissolution was obtained from VWR (Darmstadt, 
Germany). 
Figure 6:  Comparison of the deposition behavior of SNPs in a single (A1+2) and triple (B1+2) 
infiltration step by SEM visualization. Whereas a single infiltration step leads to excess 
nanomaterial in the center of the membrane, a triple infiltration allows a homogenous distribution 
by flushing SNP to peripheral pores.   
A2 B2 
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 II.2.2.1.2 Methods 
LbL Coating Procedure 
After the infiltration of SNPs into the pores, the template membranes were applied to aqueous 
solutions of pCMV-luc and bPEI. The procedure was performed in glass vials for 12 min each 
for both polyelectrolytes. During coating the membranes floated freely in the solution without 
additional stirring. A rinsing step in MilliQ water was performed after every coating step to 
get rid of excess polymer especially on the template’s surface. Since the initial charge 
provided by silica was negative, the LbL cycle (Figure 7) was always started with a first layer 
of bPEI. The pH of a 2 % (m/V) bPEI solution was adjusted to 7.0 with the addition of 0.1 M 
sodium chloride. The overcompensation of negative charges by bPEI to positive values allows 
the deposition of the plasmid DNA onto the particles’ surface in the second coating step. 
Therefore, 1 mg pCMV-luc was dispersed in 10 mL of purified water also with an additional 
0.1 M sodium chloride. The resulting coating of one LbL cycle is constituted as one double-
layer (PE+/PE-). The cycle can be repeated as often as desired, until the nanoparticles get 
interconnected with each other stabilizing the micron structure within the template pores.   
               
 
 
Figure 7: The LbL coating procedure is performed in cycles starting with the 
initial deposition of PE+ onto the negatively charged SNPs. In a second step PE- 
can be deposited due to the electrostatic attraction leading to one double-layer of 
PE coating. Adding rinsing steps after polymer deposition, the procedure can be 
performed in cycles until the coating material interconnects the individual 
nanoparticles. 
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Microrod Release from the Template and Purification 
After the deposition of the needed amount of double-layers, the templates got dried at room 
temperature. Transferred to Eppendorf tubes, the templates were exposed to 1.0 mL THF, 
which dissolved the membrane material immediately. To remove the PC and free 
nanomaterial from the sample, centrifugation at 6500 g for 7 minutes was applied. Afterwards 
the supernatant got disposed and another 1.0 mL THF was used to redisperse the particle 
pellet. The purification protocol was repeated 5 times to remove all remaining PC debris from 
the microrods.  
Agarose Gels for DNA Visualization 
For gel preparation, 0.8 g agarose NEEO were dissolved in 80 mL TAE buffer by heating at 
60 °C for 2 minutes. After cooling down to room temperature, 5 µL ethidium bromide (EtBr) 
solution (10 mg/mL) were added and the mixture was applied to the tray to solidify. The gel 
formation was completed after 30 min and the tray was applied to the electrophoresis 
chamber. Fully covered in TAE buffer, 50 µL of microrod suspension was mixed with 10 µL 
bromophenol blue-glycerine mixture as loading agent and applied to the pockets. At 80 V the 
electrophoresis was performed for 60 minutes with a consecutive fluorescence evaluation at 
Excitation 360 nm, Emission 590 nm.  
Electron Microscopy Visualization 
For visualization the regular SEM settings from last section were used. In addition to that, 
eSEM settings were used increasing the atmospheric pressure to 200 Pa allowing the sample 
to be visualized in dispersed state in MilliQ water.  
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II.2.2.1 Results and Discussion 
 
Evaluating the wide range of commercially available polycations, the ideal candidate to 
combine with the plasmid DNA had to be characterized by tolerating high charge densities for 
both engineering and application purposes. On the one hand, high charge densities are 
important for a sufficient polymer coating. Providing an environment of high electrostatic 
attraction promotes polyelectrolyte deposition and is therefore vital for the fabrication of films 
reaching the structural integrity for the resulting microparticulates. Furthermore, in the 
presented system the stabilizing agents are at the same time the active ingredient and 
transfection agent respectively. Higher polymer content due to high electrostatic forces can in 
addition contribute to a desired increase in cargo loading. On the other hand, macrophages as 
the cells of interest are able to generate harsh enzymatic and acidic conditions within 
phagolysosomes upon particle uptake. Therefore, the efficient protection and escape of 
DNA/RNA-based cargos from the disruptive environment has to be provided. While high 
buffering capacities are expected to contribute to overcome the lysosomal barrier, the 
protection is related to the DNA/RNA condensation capabilities. Transfection agents such as 
bPEI (Figure 8) show both a high buffering capacity spanning the physiological pH range and 
high condensation efficiencies for polyanions, which can both be ascribed to the ability of 
exhibiting high surface charge densities. Since the introduction of PEI in 1995 by Boussif et 
al., it is up to the present day the most investigated and commonly used agent providing high 
transfection efficiencies.[18] It was therefore the first candidate to apply to the microrod 
engineering approach in order to design a novel gene delivery system. For the monitoring of 
the progress of the LbL coating, a method was applied to prove the deposition of both of the 
excipients in a qualitative manner. Making use of the DNA intercalating properties of 
ethidium bromide, a fluorescence dye frequently used in molecular biology for the detection 
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of nucleic acids, a strong fluorescence emission can be visualized whenever the plasmid DNA 
is the outermost layer of the coating. With an additional layer of bPEI coated onto the pDNA, 
 
                               
 
 
intercalation is prevented and therefore no fluorescence signal can be detected. In Figure 9, 
the consecutive coating of 3 double-layers is presented. Due to their micron size the rods 
remain in the pockets of the gel showing no mobility. Starting the visualization in frame 1, no 
fluorescence can be detected from bPEI (PE+), whereas a signal from the EtBr staining is 
clearly visible when pCMV-luc (PE-) is applied as the outermost layer (frame 2). For the 
subsequent LbL layers the same results could be obtained allowing the following conclusions. 
Ethidium bromide-promoted fluorescence signals from pDNA layers showed the successful 
incorporation of the cargo into the microparticles. The strongly suppressed fluorescence 
signal by an additional layer of bPEI supported the assumption for the genetic material to be 
shielded to a certain degree from a potentially degrading environment, such as 
phagolysosomes. And lastly, EtBr-loaded agarose gels were introduced as an in-process 
control proving the coating procedure to be robust and suitable for the fabrication of multiple 
double-layers for microrod stabilization.    
  
Figure 8: Chemical structure of bPEI providing positive 
charges due to amino groups, which can be protonated 
within aqueous environments. 
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An important aspect about the LbL coating, which had to be adjusted carefully, was the 
concentration of additional electrolytes in the PE solutions. The first protocol for the 
presented method was established by Kohler et al. using the model PEs polyallylamine and 
polystyrene sulfonate with the addition of 0.5 M sodium chloride.[1] In a first experiment, the 
salt concentration was maintained and applied to the bPEI-pCMV-SNP system. The initial 
concentration was supported by Ren et al. who presented a study on the deposition efficiency 
of DNA into LbL layers depending on the sodium chloride concentration in the coating 
solution.[19] They found an optimum of again 0.5 M for maximum DNA incorporation 
(Figure 10).   
Figure 9: Visualization of the subsequent deposition of three double-layers bPEI//pCMV-luc onto 
the microrod system. Frames 1-6 show particle-loaded agarose gel pockets and strong signals upon 
UV excitation, whenever pCMV-luc is the outermost layer (frames 2, 4, 6). With an additional 
layer of bPEI the signal is shut down avoiding EtBr intercalation (frames 1, 3, 5). 
1
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For the presented microrod system, the displacement of hydration envelops turned out to be 
too harsh leading to an excessive PE deposition on the template surface. Even though the 
membranes were cleansed thoroughly between the different coating steps, the polymeric film 
was consistent isolating PC from the organic solvent. As a consequence, the template could 
not be dissolved, but was prepared for SEM visualization. In Figure 11 A, the template is 
shown covered by polymer layers, which are also immobilizing the microrods on its surface. 
Preventing the recovery of the particles completely, the sodium chloride concentration had to 
be reduced down to 0.1 M for unhindered release. The particles, gained after the purification, 
are characterized by high uniformity throughout the whole batch (Figure 11 B). They 
remained well dispersed in THF and did not show any tendencies for agglomeration when 
transferred to aqueous media, which was important for consecutive cell culture or animal 
studies. Looking closer at the microrods (Figure 12), it was indicated that they highly 
correspond to the template pore shape. At the surface, the polymer coating can be observed in 
filament-like structures interconnecting the nanomaterial.  
 
Figure 10: Graph by Ren et al. on the dependence of DNA 
incorporation into LbL layers on the sodium chloride concentration. 
DNA amount of the resulting layers was measured by UV 
spectroscopy at 260 nm. An optimum was found for 0.5 mol/L.[19] 
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Figure 11: Electron microscopy visualization of microrods in immobilized (A) and released (B) 
state; A: Polymer layers on the surface of the template inhibited particle release; B: Reduction 
of sodium chloride concentration led to a full dissolution of the template in THF and therefore 
released microrods.  
 
A B 
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In summary, the established engineering protocol led to the stabilization of SNPs into the 
micron structure given by the template pores. The cylindrical geometry of 10 µm in length 
and 3 µm in diameter could be maintained to build up the desired rod formation. Therefore, 
the plasmid DNA cargo and the buffering agent bPEI were successfully introduced into the 
system adding functionality for the introduction of genes into target cells. For the conduction 
of cell culture experiments, rod amounts in the milligram scale were needed. Evaluating the 
amount of particles gained from one template, the rods were weighed after drying. A mass of 
2.5 mg per template were found to be the average yield for the presented system. Scaling up 
the amount by preparing up to 15 templates in parallel, the sufficient amounts for cell culture 
studies could be easily reached. 
Figure 12: SEM close-up visualization of a bPEI-pCMV-stabilized microrod.  
A. the microrod shows high correspondence to the template pore shape. B. The 
polymer coating can be observed in fine filament-like structures 
interconnecting SNPs.  
B 
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 II.2.3 Yield Evaluation and Calculations 
 
To determine the efficiency of the engineering method, experimental data was correlated with 
the corresponding calculations. Due to their micron size, rods can be applied to a regular 
hemocytometer. Intended for the counting of red blood cells, an aliquot of the sample is 
infiltrated into a chamber featuring a grid. By visual determination using a microscope, the 
number of particles on the grid can be counted leading to an approximation for the whole 
sample. A suspension of defined concentration was used leading to a rod count of 3x106 rods 
per milligram. Including the average yield of 2.5 mg per membrane led to an overall count of 
7.5x106 microrods per template membrane. For the used membranes of 25 mm (1) in 
diameter, an average pore count of 0.02 per µm² (2) was found leading to a total pore count of 
10.95x106  (3) pores for one template membrane. The number reflects the maximum possible 
yield of microrods assuming a perfect infiltration and stabilization result. It was compared to 
the result gained from the experiments (4) leading to an overall efficiency of 75.4 % (5) of the 
engineering method.  
(1) ATemplate = πr² = π x (12.5 mm)² = 491 mm² = 4.91x108 µm² 
(2) N1 [Pores/µm2] = 0.02 
(3) N2 [ Pores/Template, calculated] = 4.91x108 µm² x 0.02 1/µm² = 10.95x106  
(4) N3 [Rods/Template, experimental] = 7.5x106 
(5) Efficiency [%] = 
7.5𝑥106
10.95𝑥106
 *100 = 75.4 
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II.3 Preliminary Cargo Release Studies in Simulated Lung Fluids 
 
II.3.1 Material and Methods 
II.3.1.1 Material  
 
For the simulated lung fluids magnesium chloride, sodium chloride, potassium chloride, 
disodium hydrogen phosphate, sodium sulfate, calcium chloride dihydrate, sodium acetate, 
sodium hydrogen carbonate, sodium citrate dihydrate and sodium hydroxide were obtained 
from VWR (Darmstadt, Germany). Citric acid, sodium tartrate dehydrate, sodium lactate and 
sodium pyruvate were purchased from Sigma Aldrich (Taufkirchen, Germany). For agarose 
gel electrophoresis the same excipients were used according to II.2.2.1.1. In addition a DNA 
ladder was used, which was a kind gift from Nicole Kuntschke, HIPS Saarbrücken.   
 
II.3.1.2 Methods 
Release Media 
 
For the production of two relevant simulated lung fluids the following compositions were 
used according to Colombo et al.[20]: 
 Artificial Lysosomal Fluid [g/L] Gamble’s solution [g/L] 
magnesium chloride 0.050 0.095 
sodium chloride 3.21 6.019 
potassium chloride - 0.298 
disodium hydrogen 
phosphate 
0.071 0.126 
sodium sulfate 0.039 0.063 
calcium chloride 
dihydrate 
0.128 0.368 
sodium acetate - 0.574 
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sodium hydrogen 
carbonate 
- 2.604 
sodium citrate dihydrate 0.077 0.097 
sodium hydoxide 6.00 - 
citric acid 20.8 - 
sodium tartrate dehydrate 0.090 - 
sodium lactate 0.085 - 
sodium pyruvate 0.086 - 
glycine 0.059 - 
pH 4.5 7.4 
 
All of the excipients were dissolved in purified water in the listed order to avoid precipitation. 
In addition a 3 M sodium chloride solution was prepared. In each solution, 1 mg of bPEI-
pCMV-SNP microrods, stabilized by 3.5 double-layers, were incubated for 7 days. The 
particles in the simulated lung fluids were incubated at 37 °C whereas the sodium chloride 
solution was heated to 80 °C. For visualization an aliquot of the suspension was applied to an 
agarose gel. 
 
Agarose Gel Electrophoresis 
The same electrophoresis method was used as in the section before to visualize the plasmid 
DNA. In addition a DNA ladder was applied covering the range from 1 to 10 kilo base pairs 
(kbp). According to the manufacturer, the applied plasmid DNA consists of 6233 base pairs 
and should be detected within the mid-range of the ladder.   
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II.3.2 Results and Discussion 
 
In the last section, the successful incorporation of plasmid DNA and bPEI into the particulate 
carrier system was shown. The fabricated films provided stability for the micron architecture 
leading to the necessary integrity for the upcoming experiments. In the subsequent step of a 
successful delivery, the cargo has to be released from the carrier at the site of action 
exclusively. Therefore the release behavior of the microrods was tested ex vivo for a first 
approach preliminary to cell culture studies. Taking into account the pulmonary application, 
two different simulated lung fluids were prepared. Upon inhalation and pulmonary deposition, 
the particles can either reside on the alveolar epithelium for a restricted amount of time or be 
engulfed by phagocytes for natural clearance. Artificial lysosomal fluid (ALF) is an analogue 
to the conditions particles are exposed to after phagocytosis by alveolar macrophages whereas 
Gamble’s solution is simulating the interstitial environment of the deep lung. According to 
literature, LbL-stabilized systems generally show high stability suggesting an extended 
incubation time, which was set to seven days.[21-23] In a parallel experiment microrods were 
incubated at non-physiological conditions (3 M saline, 80 °C) to set a release benchmark 
expecting a more pronounced destructive effect. The sample suspensions were applied to EtBr 
loaded gels to visualize the plasmid DNA on the particles’ surface or in the suspension water. 
In Figure 13, the evaluation of all incubation media after 7 days is shown. According to the 
expectations, the benchmark suspension showed DNA fluorescence signals both on the 
particles’ surface within the pockets and free migrated plasmid in the gel. The bands of 
pCMV-luc appeared in the range of 6 kbp indicated by the DNA ladder in line II.  For the 
simulated lung fluids no DNA release could be detected. However, signals from the rods’ 
surface could be observed potentially due to the electrolytes interfering with the electrostatic 
environment of the PE layers. The disrupting effect of the salts may have been strong enough 
for EtBr to penetrate into the layers reaching the DNA bases, but the full release from the 
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electrostatic interactions with bPEI could not be provided. What can be concluded from this 
study is on the one hand the confirmation for the presented system to show high stability. 
           
 
                    
 
Only benchmark conditions, which are not present in biological systems, led to a release of 
the cargo from the deposited films. On the other hand the design of the experiment did not 
include the enzymatic arsenal of phagocytes. While there is no high enzymatic activity in the 
interstitium of the lung, lysosomal enzymes of macrophages could trigger the cargo release 
highlighting the possibility of a targeted release. This could be in particular interesting for 
microrod systems featuring, in contrast to bPEI, a biodegradable transfection agent. To pursue 
this strategy, microrods were tested in presence of degrading hydrolases in the following 
chapter. 
 
 
 
 
 
1     2     3    4     5     6    7     8 
Figure 13: Agarose gel electrophoresis for the visualization of plasmid DNA extracted 
from microrods. Evaluation was carried out after 7 days of incubation. Bands: (1) DNA 
ladder as positive control: I – 1 kbp, II – 6 kbp, III – 10 kbp; (2) and (3) microrods in 3 
M sodium chloride at 80 °C as benchmark; (4) and (5) microrods in Gamble’s solution 
at 37 °C; (6) and (7) microrods in ALF at 37 °C; (8) purified water as negative control. 
 
III 
II 
I 
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Chapter III 
Microrods Featuring Biodegradability 
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III.1 Introduction: Stimuli-Responsive Drug Delivery Strategies 
 
For the rational design of advanced drug delivery systems and therefore the optimization of 
pharmacotherapy, physiological and pathophysiological conditions of the human body can be 
exploited. Since decades, acidic non-steroidal anti-inflammatory drugs (NSAID) such as 
ibuprofen are used for pain relief showing a passive targeting to the actual site of action. Upon 
oral administration and resorption, NSAID show high accumulation in the inflamed tissue due 
to low extracellular pH. Here, the acidic drug molecules are present as free bases showing 
high permeability and a subsequent intracellular entrapment due to dissociation at higher pH 
within the cytosol.[1] Promoted by recent progress in material sciences, novel carrier systems 
were created adapting the mechanism of pH-responsive targeting and also cargo release.[2] 
Besides the utilization of pH, also enzymatic activity can be used to provide a controlled 
delivery of active agents. On the one side, extracellular enzymes can be used to reach an 
improved targeting of the carrier system. Noga et al. presented a study for the fabrication of 
nanoparticles decorated with hydroxyethyl starch (HES).[3] Originally used as plasma 
expander, HES features high biocompatibility and biodegradability. Indented for intravenous 
administration within cancer therapy, they showed the HES decoration to be degraded by 
pancreatic amylase during circulation. Utilizing the enhanced permeability and retention 
effect (EPR) of solid tumors, particles accumulated in the malignant tissue as soon as a 
suitable particle size was reached.[4] On the other side, enzymatic activity can be exploited to 
provide a controlled release of the cargo. Especially for the delivery of compounds with 
cytotoxic effects, a high beneficial impact for patients can be provided while restricting the 
pharmacological effects to a target area. Bernardos et al. presented a study for the controlled 
intracellular release of doxorubicin by polysaccharide crafted silica nanoparticles.[5] They 
utilized lysosomal cleavage to reduce the chain length of the sugar polymers, which triggered 
the release of the cargo. The approach shows a specifically triggered release in a target 
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compartment with high potential to reduce side effects of the treatment where the necessary 
enzymatic activity is not present. Regarding the cargo release studies of the previous chapter, 
the utilization of new compounds for the microrod system was desired. Therefore, the 
introduction of enzyme-promoted degradability was in the focus to gain preliminary 
information about the release behavior of the particles for pDNA prior to cell culture studies. 
Taking into account the highly equipped enzymatic arsenal of macrophages as the target cells, 
applying stabilizing agents, which are substrates to lysosomal enzymes e.g. hydrolases, was a 
promising approach to trigger cargo release.[6] For the selection process of suitable excipients 
the following important parameters had to be considered. The amino functionalization had to 
be maintained to provide both positive charges for the LbL coating procedure and high 
buffering capacity at the pH range from 4 to 7. A corresponding enzyme had to be present in 
macrophages to cleave the connecting structures to a high degree enabling chain length 
reduction and therefore facilitated pDNA release. Regarding polysaccharide materials, a 
broad range of dextran derivatives can be obtained including amino-functionalized species 
such as dextran amine or diethylaminoethyl-dextran (DEAE-D), which was preferred due to 
lower costs. Along with DEAE-D, chitosan was selected as a second amino-functionalized 
polysaccharide to carry out stabilization studies for the microrod system. The subsequent 
enzyme assays were performed in comparison to bPEI systems highlighting the introduction 
of sugar derivatives as a viable approach for the introduction of stimuli-responsive release 
behavior into the particle system. 
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III.2 Microrod Stabilization by Amino-Functionalized Sugar 
Polymers and DNA 
 
III.2.1 Material and Methods 
III.2.1.1 Material 
 
For the production of microrods featuring biodegradability the same infiltration setup was 
used as in the chapter before. Nanoparticles made of silica were infiltrated into 3 µm pores of 
a PC template membrane. As amino-functionalized sugars DEAE-D 10 kDa was obtained 
from TdB (Uppsala, Sweden) and chitosan hydrochloride (CHT) 50-150 kDa (Protasan UP 
CL 113, degree of deacetylation > 85 %) was purchased from NovaMatrix (Sandvika, 
Norway). As DNA material the same plasmid pCMV-luc was used as in the previous 
experiments.  
III.2.1.1 Methods 
Layer-by-Layer Coating and Microrod Release 
 
For the DEAE-D coating solution 200 mg were dissolved in 10 mL purified water for a 
2 % (m/V) solution. The solution pH was adjusted to 7.0 and 100 mM sodium chloride was 
added. For chitosan the concentration was set to 1 % (m/V) considering the increase in 
viscosity caused by the distinct swelling in aqueous media. Using the hydrochloride salt of 
chitosan, it fully dissolved within 60 minutes without adding additional acid. The resulting 
solution appeared slightly yellow at a pH of 4.5 which was adjusted to 5.8 with additional 25 
mM saline. Both PE+ were combined with pCMV-luc (PE-) using the same LbL cycle 
protocol as in the previous chapter. The release and purification was performed accordingly 
by template dissolution in THF and centrifugation. 
 
 - 53 - 
 
III.2.2 Results and Discussion 
 
DEAE-D as the amino-functionalized derivative of native dextran is a branched 
polysaccharide exclusively composed of glucose connected by α-1,6 or α-1,3 glycosidic 
bonds (Figure 1). It is widely used in biomedical applications such as protein stabilization, 
vaccine production or as transfection agent in gene therapy.[7-9] Especially interesting for the 
utilization in LbL procedures Le Cerf et al. showed for DEAE-D that there is no significant 
increase in charge density by lowering pH even to its stability limit of 3.[10] So a higher pH       
 
                                  
 
 
 
 
for the prepared solution was favored avoiding possible acidic hydrolysis of the plasmid DNA 
in the phosphate-sugar backbone. In the context of electrostatically driven LbL cycles, 
adjusting pH values always has to be regarded as a double-edged sword. On the one side, it 
can be possible to provide increased charge density for a promising excipient, but on the other 
side the amount of polymer deposition can be reduced by high acidity of the coating solution. 
This is due to the saturation of negative charges by protonation of the coating counterpart, 
especially when using strong PE-. For CHT this effect was studied in detail by Lundin and 
Figure 1: Chemical structure of DEAE-dextran 
featuring α-1,6 glycosidic bonds of glucose in the 
straight chains. Side chain branches start from α-1,3 
linkages.    
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colleagues.[11] They investigated the deposition behavior of CHT from aqueous solutions onto 
negatively charged silica surfaces, which act as strong polyanion. Evaluated for two different 
pH values 4.2 and 5.8, they showed an increased deposition amount of CHT at higher pH due 
to an increased ratio of charged silanol groups at the template’s surface. According to the 
authors for CHT this is in particular important since it interacts as a weak base and PE+. Their 
study found its way into the presented preparation of the CHT LbL solution as the amount of 
polymer deposition is crucial for the stabilization of the microrods. In addition, a reduced 
amount of saline was added to the solution at pH 5.8 since slight turbidity could be observed 
in preliminary studies for 100 mM. In contrast to bPEI and DEAD-D, CHT turned out to be a 
demanding excipient concerning the optimum coating conditions. Built up by randomly 
deacetylated D-glucosamine units (Figure 2) CHT is a highly investigated compound  
                                           
 
 
 
combining advantageous features for biomedical applications, such as tissue engineering or 
wound dressings due to its high biocompatibility, bacteriostatic effects and low toxicity.[6, 7] 
Furthermore,  it was shown to be a versatile carrier for biological macromolecules, including 
Figure 2: Chemical structure of chitosan built up by N-acetyl-D-
glucosamine units with β-1,4 linkage. Monomers are randomly 
deacetylated due to hydrolytic treatment. 
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genetic material for cell transfection, qualifying CHT for the stabilization and 
functionalization of microrods.[12-14] For both excipients particle formation worked out leading 
to comparable yields in comparison to the bPEI systems (Figure 3). In contrast to the 
overview visualization of the bPEI batch, the sugar-stabilized batches were monitored in 
regular SEM mode under high vacuum. Therefore, the suspension is dried before measuring, 
which leads to the shown reversible agglomeration in the electron micrograph. The 
phenomenon is described as coffee ring effect caused by particle entrapment due to the 
collapse of the free surface after liquid evaporation.[15] Within MilliQ water and organic 
solvents the particles remain well dispersed and do not show tendencies for agglomeration. 
What can be concluded from the study is the confirmation for the engineering method to be 
robust for changes in excipients and layering conditions. By adjusting the coating solutions 
carefully regarding pH and saline, the deposition of PE of different charge densities can be 
provided adding new features such as enhanced biocompatibility or biodegradability to the 
carrier system. Substrate to glycoside glucosidases, DEAD-D and CHT stabilized microrods 
were expected to show a stimuli-responsive behavior enabling a triggered release of the 
plasmid DNA when applied to the right enzymatic conditions. Therefore, a protocol was 
established providing the prolonged enzymatic treatment of the rod formulations and a 
sensitive method for the measurement of the released plasmid, which will be presented in the 
following section.       
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Figure 3: SEM visualization of microrods; A. Rods stabilized by 3.5 DL of 
DEAE-D and pCMV-luc; B. Rods stabilized by 3.5 DL of CHT and pCMV-
luc. 
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III.3 Enzyme-Induced Release of DNA from Microrod Systems 
 
III.3.1 Material and Methods 
III.3.1.1 Material 
 
For the enzymatic treatment of DEAE-D and CHT microrods lysosomal α-glucosidase from 
saccharomyces cerevisiae (300 units/mg) and lysozyme from chicken egg white 
(> 40.000 units/mg) were purchased from Sigma Aldrich (Taufkirchen, Germany). For 
fluorescence measurements a Tecan Reader Infinite 200 Pro (Tecan Group, Männedorf, 
Switzerland) was used. For confocal imaging particle suspensions were applied to 8 well µ-
Slides from Ibidi (München, Germany).   
 
III.3.1.1 Methods 
Ethidium Bromide Assay for DNA Quantification 
 
For the exact determination of the released plasmid DNA, a sensitive method allowing 
reproducible measurements down to 60 ng/mL was applied. Therefore, a protocol of Bonasera 
et al. was used who proposed an improved sensitivity by switching the excitation wavelength 
from the regularly used 270 nm to 250 nm while adding 0.5 µg/mL ethidium bromide. The 
highest emission can be detected at 605 nm.[16] This was in particular important since both 
enzymes also show fluorescence activity at an excitation wavelength of 280 nm due to 
tryptophan side chains featuring indole groups. Therefore, an increased separation of the 
excitation of the DNA and the enzymes could be combined with high detection sensitivity.   
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Enzymatic Treatment of Microrods 
 
For both PE+, microrod batches were fabricated with a total polymer content of 3.5 DL. For 
the triggered release from the DEAE-D batch 1 mg microrods was incubated in an aqueous α-
glucosidase solution. The concentration of glucosidase was set to 100 units equal to 340 µg 
protein. After the addition of 50 mM sodium chloride, pH was adjusted to the activity 
maximum of the enzyme at 6.0 due to the manufacturer’s specification. The suspension was 
stored in Eppendorf tubes at 37°C in an incubation chamber. The time points for the 
measurements were set to 0 h, 6 h, 12 h and 24 h to cover a burst release. After the first day, 
the measurement was performed once per day. Therefore, the suspension was centrifuged at 
5000 g for 5 min using the resulting supernatant for analysis. For the CHT batches the same 
experimental setup was used, applying 100 units (2.5 µg) lysozyme. pH was adjusted to the 
activity optimum of 6.2. In addition, DEAE-D and CHT microrods were stored in MilliQ 
water only to evaluate the unspecific influence of aqueous hydrolysis on the system. As a 
control microrods stabilized by bPEI were incubated with and without enzymes. All batches 
were evaluated in triplets.     
Confocal Microscopy 
 
For the visual evaluation of the degradation of the microrods the previous setting including 
bPEI controls were also incubated on 8 well microscopy plates. Utilizing the fluorescence 
label FluoBlue (Excitation 354 nm/Emission 450 nm) of the SNPs, microrods can be 
visualized for a qualitative evaluation of the degradation process.  
III.3.2 Results and Discussion 
 
In a preliminary study, fluorescence spectra of the applied enzymes were measured to verify 
strong signals at the expected wavelengths (Figure 4). Maximum fluorescence emission 
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Figure 4: Fluorescence spectra of the applied enzymes α-glucosidase 
and lysozyme. Both proteins show maximum fluorescence emission 
for excitation wavelength λex = 280 nm due to indole groups of the 
amino acid tryptophan.[17, 18] 
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intensity was observed at an excitation wavelength of 280 nm for both α-glucosidase and 
lysozyme, which is linked to tryptophan residues in the amino acid sequence.[17, 18] Upon 
excitation, aromatic indole groups in the side chains showed strong emission, which was 
measured at 305 nm. However, the decisive aspect about the spectra is the absence of signals 
for the excitation at 250 nm of the pDNA quantification assay where the results did not 
exceed the values of the base line. Therefore the measuring protocol was confirmed to 
selectively determine the amount of plasmid DNA in the supernatant without potential 
deviation by the degradation agents. In a consecutive step, a calibration of pCMV-luc with the 
addition of ethidium bromide was performed (Figure 5). Results indicated a suitable linear 
correlation down to a minimum of 60 ng/mL, which was regarded as the detection limit. 
Below this value no viable and reproducible results could be obtained from the measurement.   
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Figure 5: Calibration of pCMV-luc with the intercalating agent ethidium bromide at an 
excitation wavelength of 250 nm. A linear correlation could be obtained down to the 
concentration of 60 ng/mL. Corresponding error bars were too small to be displayed. 
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Applied to the incubated particle batches, the carried out measurements of the first day 
clarified that no burst release could be observed for the microrod systems (Figure 6). 
However, DEAD-D rods showed pDNA signals after 24 h and the highest overall release. 
Lysosomal α-glucosidase as a hydrolytic enzyme breaks down α-1,6 glycosidic bonds of 
DEAE-D disrupting the stabilizing matrix. As a consequence, the dissociation of the plasmid 
DNA from the carrier is facilitated leading to the highest release rates in the presented assay. 
But also CHT microrods showed a responsive behavior to the enzymatic treatment. Applied to 
lysozyme, which cleaves β-1,4 linkages from N-acetyl-D-glucosamines, CHT microrods 
started plasmid release at day 3 with a moderate increase within the studied time frame. 
Nevertheless, the dextran-glucosidase system performed at higher velocity and efficiency 
potentially caused by CHT, which is known to form hydrogels acting as a sustaining diffusion 
barrier.[19, 20] 
For bPEI no significant pDNA release could be measured according to the previous 
experiments. The same results were obtained for DEAE-D and CHT batches, which were only 
incubated in purified water. This observation indicated that the particles do not respond to 
unspecific aqueous hydrolysis, but are able to provide a controlled release, which can be 
triggered by the choice of the applied excipients for LbL coating. Furthermore, DEAE-D and 
CHT rods showed the tendency to reach a plateau for cargo release after 7 to 8 days. This 
could be a result of the completed degradation of the sugar derivatives with a maximum of 
free DNA or a loss in enzyme activity. Considering the enzymes to be exposed to repetitive 
mechanical stress during centrifugation and temperature variations, a decreased functionality 
of the enzymes was likely to occur during the study. In addition to that, it is also possible that 
diffusion as the driving force for release decreased to a level, where it was overcompensated 
by remaining attractive electrostatic forces within the polymer matrix. To further evaluate on 
the recent findings, the incubation and degradation process was monitored by confocal laser  
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scanning microscopy. The whole setup was maintained, but transferred from Eppendorf tubes 
to 8-well microscope incubation chambers. Due to the FluoBlue fluorescence label of the 
SNPs, the micron structures could be easily monitored. As depicted in Figure 7, microrods 
show an increasing number of fragments during the observation time, but no complete 
disaggregation could be observed. The extent of fragmentation appeared higher for the 
DEAE-D batch, which would support the higher release rate and highlight a clear correlation 
between released plasmid DNA and enzymatic degradation of the carrier system.  
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Figure 6: Evaluation of the enzyme-triggered pDNA released from DEAE-D, CHT and bPEI 
batches: For an observation time frame of 9 days bPEI did not show any pDNA release according 
to previous studies. For DEAE-D and CHT pDNA signals could be observed proving a stimuli-
responsive behavior for the biodegradable excipients. 
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Summarizing the study, the conducted experiments shed light on the pDNA release behavior 
of different microrod systems. By applying amino-functionalized sugars to the LbL coating, 
microrods could be stabilized to fabricate stimuli-responsive carrier systems. Plasmid DNA 
quantification was performed over a time period of 9 days indicating a triggered release when 
exposed to the appropriate enzymatic environment. A distinct increase in free DNA was 
measured in comparison to microrods featuring a non-biodegradable transfection agent. As 
substrates to enzymes present in alveolar macrophages, DEAE-D and CHT-based systems 
A B 
C D 
Figure 7: Confocal imaging of microrods incubated with degrading enzyme solution: a) and c) 
show DEAE-D stabilized rods right after incubation and after 9 days of treatment. b) and d) show 
CHT stabilized systems at the same time points. Scale bars refer to 10 µm. 
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qualify for the controlled delivery of nucleic acid based drugs. Whereas DNA release within 
phagolysosomes after engulfment can be expected, microrods were shown to remain stable in 
absence of high enzymatic activity. This can contribute to a targeted delivery of the 
transported genetic material to the cells of interest and at the same reduce unwanted side 
effects of free DNA in in vitro and in vivo environments. 
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Chapter IV  
Technological Characterization of Microrods 
 
 
 
 
 
 
 
For section IV.1 the author of the thesis made the following contributions to the chapter: 
Design, fabrication and sample preparation of defined masses of microrods, calculations and 
interpretation of all experimental data. 
ICP-OES analysis was performed by Andrea Jung of the division Chemical Analysis at 
Leibniz Institute for New Materials (INM, Saarbrücken). 
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IV.1 Quantification of Microrod System Components 
 
IV.1.1 Introduction to Layer-by-Layer Quantification 
 
The introduction of Layer-by-Layer coating procedures to material and biomedical sciences 
prompted an increased demand of suitable analytical methods to study mechanisms and 
amounts of compound deposition. To answer this need, existing methods such as atomic force 
microscopy (AFM) were adapted allowing to measure layer thickness and showing polymers 
to be deposited in nanometer thin films.[1] Szarpak and colleagues therefore studied the 
deposition of polyelectrolytes onto microparticles in dry state illuminating deposition patterns 
and also morphological changes of the films in dependence on the number of coated layers. 
Introducing isothermal titration calorimetry (ITC) to LbL coating evaluation, mechanistic 
studies could be performed at high sensitivity giving insights into binding affinities, 
dissociation constants and thus quantitative molecular interactions of excipients. Similar to 
the presented microrod system, Chiad et al. studied the interactions of colloidal silica particles 
with different polymers.[2] For defined parameters such as temperature, solvents and polymer 
concentration, they were able to calculate binding constants giving detailed insights into 
adsorption mechanisms and therefore into film formation. By the introduction of quartz 
crystal microbalances (QCM) the monitoring of LbL films could be extended from structural 
properties and binding affinities to the determination of absolute amounts of deposited 
polymer. The technique is based on a quartz crystal showing the piezoelectric effect and 
therefore changes in resonant frequency upon film deposition. This made QCM a frequently 
used method for microgravimetry. Malmstöm et al. published a study on the evaluation of 
protein adsorption onto nanostructured surfaces utilizing QCM.[3] They used laminin as a 
model protein quantifying the amount which was adsorbed to gold or silicon substrates. The 
substrates themselves were either present as homogenous films or as colloidal particles 
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immobilized onto the QCM electrodes. They were able to identify differences in deposition 
depending on the hydrophobicity and morphology of the substrates. Their results indicated 
high amounts of protein when coated onto hydrophobic gold substrates or onto nanostructured 
surfaces leading to a more detailed understanding of the deposition of large biomolecules onto 
colloidal substrates.  
All the mentioned techniques contributed to gaining a general understanding for LbL 
principles, but they were not suitable to apply them as an in-process control during particle 
preparation. That is the reason why in many published works the layer quantification is spared 
out or performed by supernatant analysis after coating. Therefore polymer concentration is 
measured before and after coating assuming the difference to be present in the resulting films. 
When using a template-assisted approach for particle engineering, unspecific adsorption onto 
the template has to be taken into account, which will directly result in deviations for polymer 
quantification. To avoid these hurdles, a direct method for the final carrier system had to be 
introduced featuring high sensitivity for small amounts of compounds, high selectivity for 
specific excipients and low material consumption. In a publication by English et al. the 
quantification of DNA was performed by an element analysis for phosphor showing high 
sensitivity and selectivity.[4] For the microrod system this technique combined several 
advantages. On the one hand, selective cargo quantification in the range of one part per billion 
was possible and on the other hand a quantitative combustion ensuring to capture the whole 
phosphor content present in the carrier. In addition to that, the low material consumption of 
the method allowed to reserve a small fraction for quantification whereas most of the batch 
could be used for further experiments such as cell culture studies.        
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IV.1.2 Material and Methods 
IV.1.2.1 Material 
 
For the quantification of the particle composition three batches of microrods were prepared. 
The particles were prepared according to the previous protocol stabilized by 2.5, 3.5 or 4.5 
double-layers of bPEI and pCMV-luc using SNPs of 200 nm in size. ICP-OES measurements 
were carried out at a Jobin Yvon Ultima 2 (Horiba, Oberursel, Germany).  
 
IV.1.2.2 Methods 
 
Inductively Coupled Plasma – Optical Emission Spectroscopy (ICP-OES) 
 
For the determination of the pCMV-luc and SNP content ICP-OES measurements were 
performed. By determining the amount of phosphor and silicon, which are exclusively present 
in the DNA and nanoparticles respectively, the total amounts of the carrier system 
components can be calculated. Therefore 1 mg microrod samples of each batch were 
dissolved in a mixture of 0.5 mL hydrofluoric acid, 1.0 mL nitric acid and 5 mL deionized 
water. According to the operating principle displayed in Figure 1, the acid fusion was 
aerosolized using a nebulizer in combination with a high pressure (2.99 bar) argon stream.[5] 
After the introduction into an argon plasma at 7,000 K, the sample gets atomized and excited 
for light emission. For quantification light emission intensity was measured at the specific 
wavelengths of phosphor λ = 214.914 nm and silicon λ = 252.611 nm. The detected emission 
intensity is in direct proportion to the number of excited atoms in the sample solution. The 
results given by the device are calculated in mass percentages of the atom species with respect 
to the overall sample weight used for analysis. 
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Calculations for Mass Determination 
 
After gaining mass percentage results for the determined atoms, the total amount of the 
molecules within the samples could be calculated. For the plasmid DNA the complete 
sequence was provided by the manufacturer allowing to calculate a mean value for the 
molecular weight of a nucleotide (MNuc) with respect to the ratio of bases present in the 
plasmid. Applying the molar mass of phosphor MP = 30.97 g/mol, the DNA amount was 
calculated as follows assuming one atom phosphor per nucleotide: 
(1) nP = mP / MP 
(2) nP = npCMV-luc  
(3) mpCMV-luc = nP x MNuc 
Figure 1: Operating principle ICP-OES: After acidic, aqueous 
dissolution, the sample gets nebulized and sprayed into an argon 
plasma. Resulting atomization and excitation allows quantification of 
elements by emission wavelengths and intensity.[5] 
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nP – amount of substance phosphor [mol], mP – mass phosphor [g], MP – molar mass phosphor 
[g/mol], npCMV-luc - amount of substance pCMV-luc, MNuc = median molecular mass of one 
nucleotide [g/mol] 
 
For the determination of the silica content, the calculation was apparent from the simple 
chemical formula SiO2. For every mol of silicon detected by ICP-OES, two mol oxygen have 
to be added for the total amount of silica. The calculations were carried out according to the 
determination of the pCMV-luc with molar masses of silicon and silica MSi = 28.1 g/mol 
MSiO2 = 60.1 g/mol: 
(1) nSi = mSi / MSi 
(2) mSiO2= nSi x MSiO2 
nSi – amount of silicon [mol], mSi – mass silicon [g], MSi – molar mass silicon [g/mol], MSiO2 – 
molar mass silica [g/mol]  
 
IV.1.3 Results and Discussion 
 
For pCMV-luc with the size of 6233 base pairs a median molecular nucleotide mass 
MNuc = 329.569 g/mol was calculated. With the results from the phosphor determination 
summarized in Table 1, the total amount of the plasmid could be obtained for all three 
batches with increasing numbers of double layers. In the following, the exemplary 
calculations are depicted for a microrod test batch stabilized with 4.5 double-layers and a total 
sample weight of 1.21 mg: 
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(1)  nP = (2.3x10-6 g) / (30.97 g/mol) = 7.43x10-8 mol  
(2) npCMV-luc = 7.43x10-8 mol 
(3) mpCMV-luc = 7.43x10-8 mol x 329.569 g/mol = 2.45x10-5g = 0.0245 mg 
According to the calculations 0.0245 mg plasmid DNA was incorporated into the particles 
with the deposition of 4.5 DL equal to 2.02 mass percentages of the whole sample. Here, the 
system behaved due to our expectations showing an increase in cargo loading with higher 
layer counts. At the same time the silica content was expected to decrease with an increasing 
ratio of polymer coating. With the results gained from the measurements the calculations are 
carried out for the same system as for the plasmid with a sample weight of 1.77 mg:     
 
(1) nSi = 6.759x10-4 g / 28.1 g/mol = 2.4x10-5 mol 
(2) mSiO2= 2.4x10-5 mol x 60.1 g/mol = 1.45x10-3 g = 1.45 mg 
 
 
 
 
 
 
 
 
 
 
 Batch 2.5 Batch 3.5 Batch 4.5 
P [% m/m] 0.14 ± 0.04   0.16 ± 0.01   0.19 ± 0.01   
pDNA 
[% m/m] 
1.46 1.68 2.02 
Si [% m/m] 44.30 ± 0,51   39.16 ± 0.11 38.20 ± 0.79  
Silica  
[% m/m] 
94.80 83.81 81.92 
Table 1: Overview for the results gained from ICP-OES and subsequent calculations: 
For three batches of increasing LbL layer count phosphor and silicon content were 
measured. As a consequence pCMV-luc and silica content could be calculated. 
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With 1.45 mg silica in a sample of 1.77 mg in weight, SNPs represent 81.92 % of the 
microrod system. What can be concluded from the measurements and calculations is that the 
microrods are mainly composed of SNPs with nearly 95 % of total mass for the 2.5 DL batch. 
This additionally means that is it possible to stabilize the aspherical micron structure with 
only 5 % polymer content within the formulation. For the plasmid DNA only a slight increase 
of the content was observed by doubling up the layer count. However, the loading can be 
sufficient as the cargo features unique interactions within biological systems, which had to be 
evaluated in cell culture studies. By using ICP-OES, a fast and direct measurement method 
could be introduced for microrod characterization. The method shows high sensitivity with a 
sufficient amount of 1 mg sample. In addition to SEM visualization and EtBr-loaded agarose 
gels, ICP-OES is a viable tool for in-process monitoring during particle preparation.  
As there is no element, which is exclusively present in bPEI, specific data was harder to 
obtain. By applying C-H-N (carbon, hydrogen, nitrogen) elemental analysis, the nitrogen 
content of the DNA had to be assessed with respect to different nitrogen contents of the four 
bases. One could also speculate that the amount of bPEI in the system is close to the mass 
needed to reach 100 % of the applied sample weight. This would lead to bPEI contents 
ranging from 3.7 to 15.63 % (m/m) for the three analyzed batches. However, concerning the 
quantification of the system components, the measurement of pDNA loading was supposed to 
be the most important parameter concerning the biological application, which was 
successfully managed. Therefore bPEI quantification was not evaluated into more detail. 
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IV.2 Aerodynamic Properties of Microrods 
 
IV.2.1 Introduction to the Next Generation Impactor 
 
Intended for pulmonary administration, the evaluation of aerodynamic properties of microrods 
is crucial to the full carrier characterization with respect to the application purpose. For the in-
process monitoring of the engineering technique as well as for the specific design attributes of 
the particles, e.g. stimuli-responsive degradation, customized characterization methods had to 
be established and introduced to the lab routine. In contrast to that, globally harmonized 
procedures for the assessment of aerosolized particles are provided by regulatory bodies such 
as the American Food and Drug Administration (FDA) and the European Medicine Agency 
(EMA). In section 2.9.18 – “Preparations for inhalation” of the European Pharmacopoeia 
specific guidelines are given to ensure high quality of aerosolized formulations.[6] Focusing on 
particle size distribution and fine particle dose, five different devices are listed allowing the 
reproducible determination of the parameters. Outlined as Apparatus E, the Next Generation 
Impactor (NGI, Figure 1) is a state-of-the-art cascade impactor based on a horizontal design. 
Cascade impactors are designed to divide a particle population into fractions of equal size 
ranges. Applying a vacuum pump at the airflow outlet, an air stream is created throughout the 
device from the induction port (IP) into the direction of the pump. Formulation samples can 
be applied by commercially available inhaler devices at the IP. Pulled into the device by the 
the vacuum, particle sizing is realized by inertia impaction. Starting at the IP inlet, which is 
basically representing the pharynx region of the human upper respiratory tract, particles have 
to follow a 90° angle and a consecutive pre-separator, which are part of the design excluding 
larger agglomerates above 10 µm from entering the impactor. Smaller particles follow the air 
stream into the device passing 7 different nozzle stages. From stage 1 to 7 the diameter of the  
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Figure 1: Illustration of the Next Generation Impactor: A) Closed setup of the impactor featuring the induction 
port and pre-separator. B) Interior of the NGI hosting 7 nozzle stations with corresponding cups for particle 
deposition and a micro-orifice collector (MOC) as the ending stage.[6]  
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nozzles decreases and as a result the airstream velocity rises. Particles will deposit onto the 
collection cups whenever inertia exceeds the undertow provided by the vacuum pump, which 
is described as the volumetric air flow. Depending on this parameter, cut-off points for the 
nozzle stages can be created. Applying an air flow of e.g. 60 L/min will lead to cut-off 
diameters from 8.06 µm at stage 1 to 0.34 µm at stage 7 referring to the largest particle 
diameter, which is still deposited in the corresponding collection cup. Cut-off diameters will 
change by varying the undertow and therefore always have to be regarded as a function of the 
air flow inside of the device.  
Regarding the metrics, which can be calculated from the particle mass distribution of an NGI 
run, the mass median aerodynamic diameter (MMAD) is frequently used to describe 
aerodynamic particle size distribution.[7] The resulting information is used as an indicator for 
the deposition behavior of polydisperse airborne particles upon application. In addition to 
that, the fraction of particles below a critical aerodynamic diameter of 5 µm is particular in 
focus, since this particle population is expected to reach the lower respiratory tract to a high 
extend. Referred to as Fine Particle Dose (FPD) or Fine Particle Fraction (FPF) when 
expressed as a fraction to the overall dose which is applied to the inhaler, the gained results 
allow in vitro predictions, which are compliant to the regulatory guidelines.[7] In order to 
improve the aforementioned deposition behavior, recent publications suggest that particle 
shape plays a significant role. In a theoretical approach conducted by Sturm et al., aspherical 
particles were highlighted to show a higher probability to reach the deep lung compared to 
spheres of comparable volume.[8] This is due to their aerodynamic behavior mainly depending 
on their cylindrical diameter.[9, 10] By this, the elongated rod geometry may provide the 
transport of higher volumes and therefore higher drug loads to the site of action. In the 
following section the determination of MMAD and FPF for nanostructured microrods are 
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depicted evaluating the suitability of the carrier for pulmonary application and therefore the 
ability to reach the cellular target.            
 
IV.2.2 Materials and Methods 
 
IV.2.2.1 Materials 
For the NGI evaluation microrods were prepared using SNPs 200 nm and a template featuring 
3 µm pores. Using bPEI and pCMV-luc for the stabilization, the LbL procedure was 
performed according to the previous sections. For impactor application the particles were 
transferred to hard gelatin capsules (size 3, transparent, WEPA Apothekenbedarf, Hillscheid, 
Germany), which were loaded into the single dose dry powder inhaler (DPI) HandiHaler® 
(Boehringer Ingelheim, Ingelheim, Germany). For sizing the particles, the DPI was applied to 
the Next Generation Impactor, which was obtained from Copley Scientific (Nottingham, UK). 
The collection cups were coated with a mixture of 40 % Brij®35 and 60 % glycerol. The 
evaluation of deposited particle masses was performed by fluorescence measurements using 
the Tecan Reader from the previous chapter. 
 
IV.2.2.2 Methods 
Calibration of Microrod Mass Using Fluorescence 
 
For the determination of microrod masses, which deposit in the single compactor stages the 
fluorescence label of the particles was used. In contrast to microrod systems which are 
stabilized by sugar matrices the presented system was not intended to disaggregate readily 
when applied to aqueous media. As a consequence the fluorescence measurements were 
performed for the microparticles. Although particles showed fast sedimentation due to high 
masses and density, the measurement was not affected due to the bottom reading operating 
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principle of the Tecan Reader. For the calibration a serial dilution was prepared starting with a 
stock concentration of 0.5 mg/mL. Diluting the stock 1:1 up to ten times a minimum 
concentration of 490 ng/mL was prepared for measurement.        
Determination of Aerodynamic Properties using the Next Generation Impactor 
  
Prior to every NGI run the volumetric airflow was calibrated to 60 L/min suitable for the 
utilization of DPIs. To avoid bulging of the particles and therefore unwanted variations for the 
particle size distribution, the collections cups were coated with a mixture of glycerol and the 
surfactant Brij® 35. After closing the device, pre-separator and induction port were added to 
the setup. A mass of 15 mg microrods was used per NGI run. The particles were transferred 
into a hard capsule which was stored within an Eppendorf tube. To remove larger aggregates 
caused by the drying steps after engineering and to reach a sufficient flowability of the 
powder the tube hosting the capsule was applied to a Vortex for 30 mins. Showing an up-and-
down movement the capsule was kept in motion until a free flowing powder was obtained. 
Applied to the HandiHaler (Figure 2) the capsule was pierced before aerosolization.[11] The 
airflow was kept constant for 4 s before the collecting cups were flushed with water to recover 
the deposited particles. In addition to the 8 collection cups also the induction port, the pre-
separator and the capsule were evaluated.     
 
 
 
 
 
         
 Figure 2: Single dose dry powder inhaler HandiHaler: Microrods are 
applied as a single dose within a hard capsule which gets pierced prior 
to aerosolization.[11]     
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IV.2.3 Results and Discussion 
 
For the calibration of microrods based on the fluorescence label of SNPs, a linear correlation 
was obtained within the tested concentration range (Figure 3). Therefore, a suitable read-out 
of the particle amounts impacted in the collection cups was available down to a detection limit 
of 490 ng/mL. For the consecutive NGI runs the particles had to be transferred to hard 
capsules for DPI application. After fabrication and purification microrods have to be dried 
from THF resulting in a dense particle pellet at the bottom of an Eppendorf tube. To regain a 
good flowability for capsule filling, but also capsule depletion during aerosolization, energy 
input was necessary for pellet disaggregation. Therefore, particles were treated by a vortex 
before and after capsule filling. Especially with the setup shown in Figure 4, a sufficient      
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Figure 3: Linear correlation of fluorescence intensity and particle amount within the 
concentration range from 490 ng/mL to 0.5 mg/mL.  
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flowability of the particles could be reached. Inspired by the up-and-down motion of the 
capsule within the DPI, which contributes to dose depletion, the capsule was transferred to an 
Eppendorf tube. Whereas for the NGI the capsule is set in motion by the undertow of the 
vacuum, here the vortex movements provided the disaggregation of the pellet. The resulting 
mass distribution of an NGI run for the microrods can be seen in Figure 5. What can be 
concluded from Figure 5 a, which is including microrod residues of the capsule, induction 
port and pre-separator, is that the majority of the particles deposited within the preseparator. 
Here, particles deposit because of their aerodynamic diameter reaching 10 to 15 µm 
representing particle fractions not suitable to reach the lung. The results indicated that the 
particles still tended to show agglomeration when processed in dry state and the 
disaggregation procedure for the powder has to be optimized. It again has to be stated that the 
particles did not show tendencies for agglomeration when applied to aqueous media or  
organic solvents. Because of the high pronounced surface charge densities the powder also 
appeared to be very hydrophilic and hygroscopic. Therefore, exposure to air humidity also has 
to be regarded as problematic, which could be solved by blending the particles with a  
Figure 4: A hard capsule loaded with 15 mg microrods. Within an 
Eppendorf tube the capsule was kept in motion for the mechanical 
disaggregation of the particle pellet. 
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Figure 5: Evaluation of the mass distribution of microrods after an NGI run: 
A) Evaluation including the capsule (Kps), the induction port (IP), the preseparator 
(Pre) and the 8 nozzle stages. B) Evaluation focusing on the nozzle stations as part of 
the batch actually able to reach the deep lung.  
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hydrophobic agent suitable for pulmonary applications such as the amino acid L-leucine. 
Focusing on the particle fractions, which were actually able to reach the nozzle stages of the 
impactor (Figure 5 b) the highest amount can be found in stage 3 featuring a cut-off 
aerodynamic diameter of 2.82 µm, whereas stage 2 and 4 show cut-offs at 4.46 and 1.66 µm 
respectively, indicating an aerodynamic diameter close to the geometric diameter of 3.0 µm. 
The evaluation and calculation of the MMAD and FPF was performed for three microrods 
batches (Table 2). What can be concluded from the results is that the microrods show an 
MMAD suitable for pulmonary delivery also indicating a deposition within the deep lung. 
The rather low fine particle fraction of 12.6 % (m/m) supports the assumption of aggregate 
formation leading to high impaction rates. Here, the introduction of new preparation methods 
such as blending, inert gas atmosphere to exclude air humidity or more sophisticated 
disaggregation techniques could improve FPF to further optimize the aerodynamic properties 
of the microrods.    
 
  
 
 
 
 
 
 
 Batch 1 Batch 2 Batch 3 Mean Values 
MMAD [µm] 2.89 2.36 2.46 2.57 
FPF [% m/m] 14.59 9.87 13.34 12.60 
Table 2: Aerodynamic parameters calculated from 3 NGI runs: Mass median aerodynamic diameter 
(MMAD) and fine particle fraction (FPF) were determined for microrods featuring a geometric 
diameter of 3.0 µm.  
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Chapter V  
Transfection Studies on Murine Alveolar Macrophages 
 
 
 
 
 
 
 
 
 
 
 
For Chapter V the author of the thesis made the following contributions to the chapter: 
Design, fabrication and sample preparation of defined masses of microrods and interpretation 
of all experimental data. 
MTT cytotoxicity, BCA and transfection assays were carried out by Shashank Reddy 
Pinnapireddy at the Institute of Pharmaceutical Technology and Biopharmaceutics, Philipps 
University Marburg. 
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V.1 Introduction: Macrophage Transfection   
 
In chapter IV the presented microrod system was successfully shown to be cargo loaded with 
the plasmid pCMV-luc in order to evaluate the proficiency of the carrier to introduce external 
DNA into the nuclear core of a target cell line. According to the pulmonary application 
purpose, aerodynamic properties were determined showing the microparticles to be qualified 
to reach the deep lung and therefore the site of action. The following chapter is dedicated to 
the consecutive steps after deposition within a biological environment. In a first step the 
engulfment by phagocytes had to be shown, which is a crucial and rate limiting step for the 
intended cargo delivery. For cell culture studies the alveolar macrophage cell line MH-S was 
chosen, originally isolated from bronchoalveolar lavage of BALB/c mice showing adherent 
behavior and typical macrophage morphology.[1] For the coating design the introduced 
transfection agents DEAE-D, CHT and bPEI were discussed prior to transfection experiments. 
Up to this point, the cargo release from bPEI microrod systems was not clarified. Whereas no 
release was shown within a simplified enzyme assay setup, literature showed similar systems 
to work efficiently under in vitro conditions.[2-4] Furthermore, bPEI shows superior 
transfection efficiencies compared to other compounds throughout a very large number of 
publications, which is in particular interesting as macrophages are known as hard to 
transfect.[5-7] DEAE-D and CHT could possibly lack the sufficient protection of the plasmid 
and buffering capacity, which is crucial when targeting macrophages with a highly disruptive, 
enzymatic arsenal. As a result, bPEI was chosen as lysosomal buffering agent for the 
transfection studies.  
With the introduction of Layer-by-Layer technologies into gene delivery, numerous novel 
systems were presented for the controlled release of genetic material.[8-10] Both the protection 
and targeted delivery of small and fragile RNA molecules, such as siRNA, or large plasmids 
can be provided.[2, 11] But besides achieving a general protein expression it was in particular 
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interesting for us to evaluate the possibility to control luciferase expression patterns by the 
design choices for the LbL coating. This is in general not an easy task, taking into account 
that intracellular mechanisms such as the escape of the transported DNA from the 
phagolysosome and nuclear transport within the cytosol will influence the results of the 
experiments. The first parameter with a potential influence was cargo loading. Expecting a 
transient transfection of the macrophages, we hypothesized that higher pDNA loading could 
maintain the expression over a longer time frame. The second parameter was the position of 
the genetic material within the coating. Pavlov et al. published a work on LbL assembled 
microcapsules evaluating the position of a plasmid for the transfection of the human 
embryonic kidney epithelial cell line 293 T.[12] They found the transfection to be more rapid 
and effective for pDNA in the outermost layer whereas no transfection was observed from 
layers which were located in inner positions of the LbL meshwork. For particles using PEI as 
the outermost layer they did not observe a difference in transfection from inner layers to those 
closer to the surrounding medium, which were indeed surprising results considering cargo 
release dependent on diffusion rates. In contrast to that, another study published by Reibetanz 
et al. showed a positive transfection from mid layers using the same cell line and protamine as 
a transfection agent.[13] The examples from literature give first insights into LbL mediated 
gene delivery revealing a high dependence on applied excipients and LbL design. Up to now, 
there are no comparable studies carried out on macrophages revealing transfection kinetics or 
demonstrating how design changes within LbL coatings can be utilized to create optimized 
expression patterns. In the following, different microrod formulations were applied to MH-S 
cells introducing LbL design parameters into macrophage transfection. 
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V.2 Materials and Methods 
 
V.2.1 Materials 
 
For cell culture studies microrods were fabricated using SNPs 200 nm with a red fluorescence 
label (Excitation/Emission 569 nm/585 nm) and template membranes featuring 3 µm pores. 
For the stabilization and functionalization bPEI (25 kDa) and pCMV-luc were applied. As a 
substitute to the plasmid DNA dextran sulfate (10 kDa) was purchased from TdB (Uppsala, 
Sweden).  
The studies were carried out on the murine alveolar macrophage cell line MH-S (CRL-2019™), 
which was obtained from the European Collection of Authenticated Cell Cultures/Public 
Health England (ATCC, Salisbury, UK). For cell culture RPMI-1640 medium (Capricorn 
Scientific, Ebsdorfergrund, Germany) was used, which was substituted with glutamin, 2-
mercaptoethanol and fetal bovine serum purchased from Sigma Aldrich (Steinheim, 
Germany). For the evaluation of cytotoxicity, assays were performed using thiazolyl blue 
tetrazolium bromide (MTT, Sigma Aldrich). The positive control was carried out using Triton 
X-100 (Sigma Aldrich). Absorbance measurements were carried out using a BioDoc Analyse 
Ti5 trans-illuminator (Whatman Biometra, Göttingen, Germany) 
Transfection studies were performed using jetPEI as a positive control (Polyplus transfection, 
Illkirch, France). The determination of bioluminescence was performed by applying the 
Luciferase Assay Kit and Cell Lysis Buffer provided by Promega (Mannheim, Germany). For 
the quantification of protein amounts Pierce Protein BCA assay kits were used (ThermoFisher 
Scientific, Darmstadt, Germany). The visualization by confocal microscopy was enabled by 
Concanavalin A:Alexa Fluor 488 Conjugate and DAPI staining (Fisher Scientific, Schwerte, 
Germany). Therefore cells were seeded onto 8-well tissue culture-treated slides (Ibidi, 
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Martinsried, Germany). Fluorescence micrographs were taken by the confocal laser scanning 
microscope LSM 710 (Carl Zeiss Microscopy GmbH, Jena, Germany).   
 
V.2.2 Methods 
LbL Coating Design 
To evaluate the influence of the LbL coating design on cellular protein expression, different 
particle batches were fabricated. In the first experiment the influence of cargo loading was 
addressed, adjusting the double-layer amount to 2.5, 3.5 or 4.5 to create three batches of 
increasing cargo loading. For both the first and last layer of the coating bPEI was used since 
the provided amino groups are required to coat negatively charged silica as well as for the 
intraphagolysosomal buffering capacity upon engulfment by the cells. For the second study 
the overall polymer content was adjusted to 3.5 DL for all the fabricated batches. The same 
amount of plasmid DNA was applied incorporating only one layer and shifting its position 
within the coating. As a substitute to the genetic material dextran sulfate (Figure 1) was used 
providing negative charges and stable films for the system in combination with bPEI. As a 
result three particle batches containing pCMV-luc in the innermost, mid or outermost layer 
were produced. The influence of the parameters cargo loading and position on protein 
expression was evaluated within identical experimental setups. 
Cell Culture  
According to the supplier’s recommendations, macrophages were cultured in RPMI-1640 
medium based on glucose, saline, amino acids and vitamins with the addition of 2 mM 
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glutamine, 0.05 mM 2-mercaptoethanol and 10 % (V/V) fetal bovine serum. Incubation 
conditions were maintained at 37 °C and 5 % carbon dioxide in humid atmosphere. The cells 
were grown in monolayers and passaged as soon as 70-80 % of confluence was reached. 
Uptake Visualization by Confocal Microscopy 
MH-S cells were seeded into 8-well plates at a concentration of 2x105 cells per milliliter 
medium and incubated at 37 °C/5 % carbon dioxide. After 24 hours fresh medium containing 
1x107 microrods per milliliter was added per well and again the plates were stored in the 
incubator. After defined time points of 0.5, 1, 2 and 4 hours of incubation cells were fixed 
with cooled methanol for 30 minutes. After two times washing with PBS buffer (pH 7.4) the 
cells were incubated with the lectin Concanavalin A (ConA), which was conjugated to the 
green fluorescent dye Alexa Fluor 488 (Figure 2). ConA selectively binds to terminal α-D-
mannosyl and α-D-glucosyl groups, which are present in MH-S actin filaments leading to a 
green fluorescence labeling (Excitation/Emission 495 nm/519 nm). For counterstaining of the 
nuclear core 4',6-diamidino-2-phenylindole (DAPI) was used. DAPI as a small molecule can 
diffuse into the cytosol of any cell strongly binding to DNA in the nuclear region especially 
Figure 1: Chemical structure of dextran sulfate 
featuring negative charges as a substitute to plasmid 
DNA within LbL coatings. 
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when it is rich in adenine and thymine content. Upon binding, DAPI shows high absorption at 
wavelength 358 nm and emission at 461 nm within the blue spectrum. The fluorescence setup 
is completed by the red labeling of the microrods enabling the visualization of the uptake of 
the particles into the macrophages by phagocytosis.  
 
                       
 
 
 
 
 
 
 
10 µm 
Figure 2: MH-S cells with DAPI staining (blue) of the nuclear core 
and Alexa Fluor 488 staining (green) of actin filaments provided by 
ConA. 
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MTT Cytotoxicity Studies  
In order to prove the microrods to be well tolerated by the cells, MTT cytotoxicity assay was 
performed. Within a defined concentration range from 1.05 mg/mL to 16.4 µg/mL, 
macrophages were incubated with the particles for 48 hours. After two times washing with 
PBS buffer containing calcium and magnesium, medium containing MTT assay reagent was 
added to each well. Cells were incubated for another four hours giving viable MH-S time to 
metabolize MTT within their mitochondria leading to a reduction to formazan (Figure 3).[14] 
Formazan appears as insoluble, purple crystals, which can be transferred into a colored 
solution by the addition of 300 µL dimethyl sulfoxide (DMSO). Cell viability can be 
determined as a function of formazan absorbance at wavelength 570 nm.   
 
 
 
 
 
Figure 3: MTT assay read-out: Viable MH-S cells reduce MTT enzymatically, which will lead to the 
precipitation of formazan crystals. The concentration of formazan can be measured by a spectrophotometer 
giving information about the viability of the incubated cells.[14] 
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Transfection Assays 
Macrophages were seeded onto 24-well plates at a density of 10,000 cells per well. The 
following day, 50 µg microrods per batch, diluted to a final volume of 100 µL with serum free 
RPMI-1640 medium, were added dropwise into wells containing 900 µL of RPMI-1640. In 
addition to that, the same amount of microrods was applied to MH-S, which were pretreated 
with chloroquine (RPMI-1640 medium with 10% FBS and 100 µM chloroquine), a known 
inhibitor of endocytosis, to exclude alternative uptake mechanisms to phagocytosis.[15] The 
commercially available transfection system jetPEI was used as positive control for the 
experiments. After particle addition all plates were swirled and returned to the incubator. All 
the transfection experiments were performed in triplicates and each experiment was repeated 
thrice. 
Luciferase Assay and Protein Analysis 
To determine the introduction of the transported plasmid DNA into the nuclear core of MH-S, 
the luciferase reporter gene was utilized. Upon successful implementation the enzyme 
luciferase is expressed by the cells. When applying its natural substrate D-luciferin, luciferase 
provides the oxidation to oxyluciferin under the emission of bioluminescence, which can be 
measured as a read-out (Figure 4).[16] Using luciferase as reporter gene combines several 
advantages. On the one hand, luciferase is not naturally expressed in mammalian cells so 
there is no background regarding the measurement and detected bioluminescence can be 
exclusively associated with the successful transfection. On the other hand, the method is 
extremely sensitive and highly reproducible with standardized protocols. For the measurement 
the transfected cells were lysed after defined time points of 2, 4, 7 and 9 days. Therefore, cells 
were washed twice with PBS buffer before the lysis agent was added. Lysate aliquots of 20 µl 
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were added to white opaque microtiter plates or clear transparent bottom microtiter plates for 
the luciferase assay or BCA protein analysis respectively. For luciferase assays, the opaque 
plate containing lysate was measured within a plate reader equipped with an autoinjector. The 
device pumps the luciferase assay mixture containing D-luciferin and the cofactors adenosine 
triphosphate (ATP) and magnesium. Therefore aliquots of luciferase assay reagent (ATP, Mg) 
and the luciferin substrate were freshly thawed, mixed and primed into the pump. A protocol 
was used with a 10 seconds integration time for luminescence detection. The instrument 
automatically pumped the luciferase assay mixture into each well and measured before 
proceeding to the next. Protein quantification was performed using a Pierce Protein BCA 
assay kit according to the manufacturer’s protocol. Based on a colorimetric assay, copper(II) 
gets reduced to copper(I) by peptide bonds within an alkaline environment. Here, the reduced 
amount of copper is proportional to the full amount of protein in the sample. In a second step 
Figure 4: Luciferase read-out: Luciferase oxidizes D-luciferin to 
oxyluciferin in presence of the cofactors ATP and magnesium. 
The enzymatic reaction occurs under the emission of 
bioluminescence and hydrolysis of ATP into AMP and 
pyrophosphate (PPi).[16] 
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copper(I) chelates two molecules of bicinchoninic acid resulting in a purple complex which 
was quantified at wavelength 570 nm. By determining the amount of protein in combination 
with the bioluminescence the overall results of the transfection are expressed in relative 
luminescence units (RLU) per milligram protein.   
 
V.3 Results and Discussion 
For every successful gene delivery approach the first und important step is the full 
invagination of the carrier into the target cells. Regarding the size of the presented 
microparticle system featuring 10 µm in length, phagocytosis is the only possible pathway for 
cellular uptake of objects that large.[17] Upon pulmonary application, epithelial cells are 
generally not able to engulf the microrod system indicating a targeted delivery to phagocytes 
according to the intended delivery approach. Professional phagocytes such as neutrophils and 
monocytes/macrophages are the only cell populations capable of actin-driven uptake of 
particles exceeding a size of 0.5 µm. The confocal laser scanning microscopy visualization 
shown in Figure 5 indicated an active uptake process of the rods into alveolar macrophages. 
Particle batches were also applied to MH-S, which were treated with chloroquine, an inhibitor 
of endocytosis, which did not affect luciferase expression excluding endocytosis as a relevant 
uptake mechanism. To achieve high uptake rates, two studies were taken into regard focusing 
on particles’ geometry. Champion and Mitragotri published a work evaluating the influence of 
the particle diameter on uptake efficiency by alveolar macrophages. Illustrated in Figure 6, 
they clearly showed a peak in uptake for two particle species when adjusting the diameter to 3 
microns.[18] In a second study their group showed that also aspect ratio plays a significant role 
for the uptake rate. Here, they found that aspect ratios round about 3 showed even higher 
internalization rates than spherical particles of comparable diameters.[19] 
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Figure 5: Fluorescence micrograph depicting MH-S 
alveolar macrophages during uptake of microrods (red) 
after 1 hour of incubation.  
10 µm 
Figure 6: Evaluation of uptake efficiency by rat alveolar 
macrophages in dependency of particle diameter for two particle 
species.[18] Figure was displayed with permission from the journal. 
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Both parameters were taken into account and due to the template-assisted engineering 
technique they could be easily introduced to the carrier system. After imaging the uptake into 
the target cells, particles had to be shown to be well tolerated. Therefore MTT cytotoxicity 
assay was performed, testing three particle batches of increasing polymer content stabilized 
by 2.5, 3.5 or 4.5 DL of bPEI and pCMV-luc (Figure 7). The tested microrod concentrations 
showed high cell viability especially below a concentration of 1.05 mg/mL. For the 
consecutive transfection studies a concentration of 50 µg/mL was chosen to yield high 
macrophage viability of 90 % and above for all three formulations. Two different design 
parameters of the LbL coating were in the focus for evaluation. On the one side increasing 
amounts of cargo loading were tested and on the other side we were curious about the  
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Figure 7: MTT cytotoxicity assay for three microrod batches of increasing polymer content. 
MH-S cells were incubated at a concentration range from 1.05 – 0.0164 mg/mL. Triton-X 
on MH-S was used as a negative control whereas untreated cells were used as a positive 
control. 
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influence of the position of the pDNA within the LbL coating on protein expression. Starting 
with increasing pDNA amounts, the microrod batches from the MTT evaluation were applied 
to MH-S for defined time frames of 2 to 9 days. Within the particle system the plasmid DNA 
acts both as a stabilizer component for the microrod architecture and as the active agent, so its 
delivered amount most likely influences the extent of protein expression, but also the integrity 
of the carrier system itself. In this regard, for the first in vitro study the initial assumption was 
that every additional layer of DNA can increase protein expression in the target cells, but will 
sustain its own release at the same time due to higher attracting electrostatic interactions. 
Results from the performed luciferase assays indicated a successful luciferase expression by 
MH-S for the prepared batches depending on the LbL coating design (Figure 8).    
   
 
 
Figure 8: Luciferase assay for three particle batches µR 1 - µR 3 of increasing cargo 
loading. Luciferase activity was measured 2, 4, 7 and 9 days after transfection. jetPEI was 
used as a positive control, untreated cells as a negative control. Bioluminescence is depicted 
in relative light units (RLU) per milligram protein including SD for n = 6. 
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Protein expression was associated with time and a steady increase in luciferase activity has 
been detected for every batch up to day 9 of the experiment. For the commercial transfection 
reagent jetPEI, we already observed a decline after the 4th day of transfection. For all three 
formulations, the same pattern in luciferase expression over time was observed showing 
differences in the total protein amount. The results supported our hypothesis that for every 
time point measured, particles even though loaded with higher DNA amounts provided lower 
amounts of protein.   
Regarding cargo release, it has to be stated that faster kinetics do not automatically lead to 
improved delivery efficiencies. Specific pharmacokinetic hurdles have to be respected 
especially when applied to challenging biological environments. For the applied particle 
system featuring bPEI as a non-biodegradable transfection agent, cargo release is most likely 
driven by diffusion. Provided by the saturation of negatively charged phosphate groups by 
phagolysosomal protons, the genetic material forfeits the electrostatic attraction to bPEI, 
which enables the diffusion out of the LbL meshwork and into the lumen of the 
phagolysosome. As a consequence, the amount of released pDNA available for nuclear 
transport depends on the diffusion of protons into the polymer layers and the consecutive 
diffusion of the DNA into the opposite direction. In addition to that, the acidic environment 
can also lead to a higher degree of protonation of bPEI resulting in high repulsive forces for 
the polymer chains and therefore spaces of facilitated diffusion of the plasmid. It is obvious to 
expect faster release rates from pCMV-luc layers, which are closer to the surrounding acidic 
medium, but this does not necessarily result in higher protein expression. Therefore, the 
transfection agent has to provide the phagolysosomal escape, which is a time-dependent step 
during gene delivery. For the presented particle system the highest luciferase expression can 
be expected from pDNA layers which show the best match of release and bPEI promoted 
escape from the degrading environment. To evaluate on this, again three batches of microrods 
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were fabricated and the polymer content was kept constant at 3.5 DL. For the positive charges 
bPEI was maintained, for the negative charges one layer pCMV-luc and two layers dextran 
sulfate were used. Thereby, the single DNA layer was shifted in its position within the coating 
to produce three different batches of microrods, whereas the dextran derivative acted as a fill-
in. The rest of the experimental setup was kept identical to the previous transfection. Again, 
studied for defined time frames of 2 to 9 days after application, successful transfection of 
MH-S could be repeated (Figure 9). 
 
 
 
Highest luciferase activity was observed for batch µR 5 featuring pCMV-luc in the mid 
position and showing RLU/mg values comparable to the first assay (Figure 8). For batch 
µR 4 featuring pDNA in the innermost layer, lower signals were measured according to 
Figure 9: Luciferase assay for three particle batches µR 4 - µR 6 stabilized by 3.5 DL using bPEI, 
pCMV-luc and dextran sulfate. The position of the single pDNA layer within LbL coating was shifted 
from the innermost layer (µR 4) to the outermost layer (µR 6) to create three different microrod 
formulations. Time frame and controls were maintained from the previous assay. Bioluminescence is 
depicted in relative light units (RLU) per milligram protein including SD for n = 6. 
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longer diffusion tracks and therefore sustained release behavior. For the batch with the 
plasmid in the outermost layer (µR 6) the lowest signals were measured. According to the 
previous remarks, the reduced luciferase activity can be associated to high enzymatic 
degradation of the genetic material. For all three batches µR 6 most likely made the DNA 
available at the highest velocity before the integrity of the surrounding vesicle could be 
reduced by the transfection agent. Whereas in the first transfection study multiple DNA layers 
could compensate the degradation of the outer layer, the reduced loading yielded in low 
signals. Additionally, the reduced loading led to a decrease of luciferase activity after day 7 
indicating a transient character of the transfection. 
What can be concluded from the in vitro studies on alveolar macrophages is an active uptake 
process of aspherical microparticles by phagocytosis. The formulations were able to provide a 
successful and transient introduction of genetic material into the nuclear core. Microrods were 
also shown to be superior to the commercially available transfection system jetPEI for 
prolonged DNA delivery. Therefore two parameters loading and position were shown to 
influence protein expression giving insights into Layer-by-Layer-promoted transfection 
kinetics of MH-S cells. Showing high enzymatic degradation, the incorporation of the DNA 
cargo into the outermost layer is not suitable for efficient delivery indicating the highest 
protein expression from inner layers. A single application of microrods provided protein 
expression over a period of at least 9 days qualifying the system as a continual genetic 
engineering system for alveolar macrophages.    
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Chapter VI 
Transfection Studies on BALB/c Mice 
 
 
 
 
 
 
 
 
 
For Chapter VI the author of the thesis made the following contributions to the chapter: 
Draft and submission of the animal proposal 16/2016 to the local government (Landesamt für 
Verbraucherschutz Saarland, Saarbrücken); design, fabrication and sample preparation of 
defined masses of microrods and interpretation of all experimental data. 
Microrod application to BALB/c mice, macrophage collection and the preparation of tissue 
cross-sections were performed by Bodo Wonnenberg and Andrea Rabung at the Institute of 
Anatomy and Cell Biology, Medical Faculty, Saarland University. 
Transfection assays were carried out by Shashank Reddy Pinnapireddy at the Institute of 
Pharmaceutics and Biopharmaceutics, Philipps University Marburg. 
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V.1 Introduction: Mouse Lung Models   
 
In biomedical research the mouse is the most frequently used animal model.[1] This is due to 
the advanced knowledge of the murine genome featuring high synteny with those of 
humans.[2] As a consequence many murine disease models were developed in order to identify 
corresponding human genes, which are responsible for the studied disease phenotype.[2] 
Especially in the fields of oncology and immunology, murine physiological and 
pathophysiological cascades have been analyzed in high detail offering basic research, but 
also pharmaceutical companies a broad range of in vivo models.[3]  
For alveolar macrophages as the target cells of the presented gene delivery approach, 
participation in inflammatory conditions of the lung, such as pulmonary fibrosis or chronic 
obstructive pulmonary disease, was shown.[4, 5] To further study the role of macrophages for 
these diseases, mouse lung models were established. Harvey and colleagues published a work 
on the stimulation of the phagocytic activity of alveolar macrophages by a natural 
compound.[6] They could successfully show an enhanced clearance of harmful bacteria, such 
as Haemophilus influenza and Pseudomonas aeruginosa, and a reduced inflammation in the 
murine lung revealing the importance of a specific pathway, which is vital for antibacterial 
defense. On this basis, they were able to translate their findings into a clinical trial for COPD 
patients who correspondingly suffer from decreased phagocytic activity of alveolar 
macrophages and persistent bacterial infections. Regarding pulmonary fibrosis, various 
models were introduced applying different methods to induce the known scar-like changes 
within the murine lung. One of the most frequently used methods utilizes the side effect of an 
active agent called bleomycin.[7] Commonly used in cancer treatment, the drug causes the 
typical histologic patterns in mice lungs, which are known from human patients. Macrophages 
have been shown to be involved in the development of bleomycin-induced fibrosis offering an 
in vivo system for the detailed study of their role within this ultimately fatal disease.[8] In 
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addition to inflammatory conditions, also murine lung models for the evaluation of malignant 
diseases are available. Herein, alveolar macrophages were shown to promote neoplastic 
growth dependent on their polarization to different subsets and therefore mediator secretion 
patterns.[9]  
For both inflammatory and malignant diseases, murine lung models are available to study the 
role of alveolar macrophages both for the onset of the disorder and the progression. As 
outlined in chapter I, gene therapy is a viable approach to address macrophages in order to 
find new treatments for such serious conditions mentioned before. Therefore, aspherical 
microrods can act as a potential delivery system. In a first step, the successful transfection had 
to be translated from in vitro to in vivo conditions within a proof-of-concept study. The uptake 
of the rods into the target cells had to be shown within a more complex biological 
environment as well as the implementation and transcription of the encoded gene. In addition, 
the carrier must be well tolerated and non-toxic to the animals to reach the planned end points 
of the experiment. In the following chapter, the in vivo evaluation of the transfection 
proficiency of aspherical microrods is presented applying the carrier system to a BALB/c 
mouse lung model.        
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VI.2 Material and Methods 
 
VI.2.1 Material 
 
Microrods were fabricated using SNPs 200 nm with a green fluorescence label 
(Excitation/Emission 485 nm / 510 nm) and template membranes featuring 3 µm pores. For 
the Layer-by-Layer coating bPEI (25 kDa) and pCMV-luc were applied. The placebo 
formulation was stabilized by bPEI in combination with dextran sulfate (10 kDa). 
The studies were carried out on female BALB/c mice obtained from Charles River 
Laboratories (Sulzfeld, Germany). For the collection of alveolar macrophages Cytospins 
(ThermoFisher Scientific, Darmstadt, Germany) were used. The subsequent transfection 
studies were performed according to the procedure as presented in chapter V using 
transfection and cell culture lysis reagent purchased from Promega (Mannheim, Germany). 
The bioluminescence was measured using a BioDoc Analyse Ti5 trans-illuminator (Whatman 
Biometra, Göttingen, Germany) 
VI.2.2 Methods 
Layer-by-Layer Coating Design 
For the transfection studies in vivo, the polymer content of the microrods was set to 3.5 
double-layers. The intermediate amount of the in vitro setting was chosen to compromise 
transfection efficiency within the planned time frame and rod stability giving respect to the 
more challenging application before reaching the site of action and therefore the target cells. 
In addition to that, for all tested concentrations microrods featuring 3.5 DL showed the 
highest MH-S viability in the performed MTT assay. To minimize differences in rod 
properties the placebo formulation was also set to 3.5 DL with dextran sulfate used as a 
substitute to the plasmid DNA in every double-layer.     
 - 106 - 
 
 
BALB/c Keeping, Anesthesia and Microrod Application  
50 female BALB/c mice were caged in a controlled and pathogen-free environment. They 
were granted unlimited excess to water and chow for the whole duration of the study. After 
reaching an age of 8 to 10 weeks (Figure 1 A), the application of the microrods was 
performed. Therefore mice were divided into 5 groups of 10 animals. The first two groups 
were used as control without any microrod application or using the placebo formulation. To 
study transfection proficiency of the pCMV-luc loaded particles, three time points were 
evaluated in correspondence to the in vitro setup. After 4, 7 and 9 days animals were 
analyzed, sparing out the evaluation after 2 days. This was due to very low luciferase signals 
in the cell culture studies, which were expected to be even lower after application to a 
demanding biological environment. At the day of microrod application, mice were 
anaesthetized one at a time using isoflurane within an inhalation chamber shown in Figure 1 
B - D. The consecutive particle application was performed by nasal instillation of microrods 
dispersed in isotonic water containing 0.9 % (m/V) sodium chloride. Placed on their back, 
aliquots of 10 µL were applied to the nostrils of the mouse in an alternating manner up to a 
maximum of 60 µL and therefore 100 µg of particles (Figure 1 D). After application mice 
were returned to the cage for recovery. During observation time, the animals were regularly 
checked for signs of sickness such as loss of fur, weight reduction or breathing difficulties and 
apathetic behavior as a result to pneumonia. According to the guidelines of the local 
government animals suffering from these conditions would have been removed from the 
study.       
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Figure 1: BALB/c mice during caging (A) and microrod application. Placed into an 
inhalation chamber (B) mice were treated with isoflurane (C) to facilitate microrod 
application (D). 
A B 
C D 
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Transfection Studies 
For analysis the same protocol was applied to all the tested groups. Alveolar macrophages 
from the mouse lung were collected performing a bronchoalveolar lavage. Therefore the lung 
was flushed three times with 800 µL PBS buffer (pH 7.4) using a tracheal cannula. As a 
single washing step the obtained cell suspension was centrifuged at 300 g and 4 °C with a 
consecutive redispersion in PBS buffer after supernatant disposal. To isolate macrophages the 
centrifugation at 300 g was repeated using a Cytospin, which allows cell separation due to 
size and density. The following steps of cell lysis and luciferase determination were carried 
out according to the protocol described in the previous chapter.      
 
Histology 
In addition to the collection of alveolar macrophages by bronchoalveolar lavage, lung tissue 
cross-sections were evaluated. Therefore, after lavage the mouse lungs were filled with gel 
and snap frozen. Kryostat sections were prepared with haematoxilin and eosin staining to 
determine inflammatory changes of the epithelium. In case of inflammation, the alveolar septa 
and epithelium would be thickened due to inflammatory infiltrate in combination with an 
apparent hyperplasia of neutrophils and alveolar macrophages. Haematoxylin is applied for 
nuclear staining and binds to DNA and RNA molecules due to electrostatic interactions. As a 
result the cellular core appears in a dark blue colour, which can be observed in dark spots. The 
counterstaining was performed by eosin, which binds to positively charged arginine and 
lysine residues of proteins resulting in a red to pink color. Non-stained sections were applied 
to a fluorescence microscope for the visualization of microrods ingested by residential 
macrophages.   
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VI.3 Results and Discussion 
 
The first important aspect about the animal studies, which had to be discussed, was the way of 
particle administration. The most suitable way for the carrier system intended for pulmonary 
application is the aerosolization of the dry powder. The main drawback of this approach is the 
missing information about the dose, which is taken up by the mice depending on the 
respiratory rate of the individual animal. In order to get more information about the delivered 
dose actually reaching the site of action to correlate with the experimental read-out, nasal 
instillation was preferred for microrod administration. Instillation is a very simple and 
therefore the most widely used technique for the pneumatic introduction of material into the 
lungs of mice managing delivery without expensive equipment and devices.[10] In addition, 
during the procedure the risk of injury for the animals is very low in comparison to intubation 
methods.[10] Eyles et al. presented a study evaluating the efficiency of microsphere deposition 
by nasal instillation. Depending on parameters such as the choice of the anesthetic agent, 
suspension media and especially dose volume they observed an average pulmonary deposition 
rate of 50 %.[11] Using isoflurane for anesthesia and PBS buffer for particle suspension, they 
applied a maximum of 50 µL to BALB/c mice to reach highest deposition efficiency in 
comparison to lower dose volumes. This was also in accordance with the experience of our 
cooperation partners at the university hospital in Homburg allowing us to adjust the dose of 
microrods reaching the lung to the same amount, which was used in the previous cell culture 
studies. The animals were observed for a maximum time period of 9 days showing no 
negative reactions to the carrier. No signs of sickness were observed for any mouse, so the 
experiment could be carried out to the planned ending points with all the animals. The 
observation for the rods to be well tolerated was supported by histology samples  
        A 
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Figure 2: Cross-sections of the alveolar region from BALB/c mice. Sections were 
stained with haematoxylin and eosin showing tissue after 4 (A) and 7 (B) days after 
microrod application. The absence of inflamed sections indicated to particles to be well 
tolerated.    
Blood Vessel Alveolus 
B 
A 
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from the mouse lung displayed in Figure 2. The alveolar tissue can be observed in its typical 
morphology after cutting the bubble-like structured alveoli. It appears in a normal, healthy 
state throughout the study without an increased infiltration of immune cells such as 
neutrophils as sign of acute inflammation. Additional information, which could be gained 
from the cross-section, was the visualization of the microrods within the interstitium. 
Therefore, the green fluorescence label of the SNPs was excited revealing the rods to be 
exclusively associated to alveolar macrophages in an ingested state. In Figure 3 (white 
arrows) particles were visualized 4 days after instillation. This observation was highly 
important for us as it indicated a successful targeted delivery of the carrier and therefore the 
cargo to the cells of interest under in vivo conditions. After the set time frames of observation 
animals were analyzed. Alveolar macrophages were extracted from the mouse lung by 
bronchoalveolar lavage and treated due to the luciferase assay protocol. Results from the 
Figure 3: Fluorescence microscopy visualization of microrods after engulfment into alveolar 
macrophages within the alveolar tissue. By excitation of the green fluorescence label of the 
particles, they can be shown to be exclusively associated to the cells (example white arrows). 
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assay are shown in Figure 4 indicating a successful implementation and transcription of the 
delivered model gene. For the placebo rods (P1-P10), which were applied as a negative 
control, no luciferase activity was found. For the plasmid DNA-loaded particles 
bioluminescence was measured for 50 % of the animals after 4 days of transfection at very 
low values. After 7 days a more pronounced signal pattern could be observed for 90 % of the 
mice showing bioluminescence values within a quite narrow range. For the results after 9 days 
again a higher fluctuation was obtained with very high maximum values, but also 40 % of the 
animals showing no luciferase activity.  
What can be concluded from the study is a correspondence to the expression patterns gained 
from the in vitro studies on MH-S cells. An increase in luciferase activity over time can also 
be observed for in vivo conditions. The in vivo situation expands the biological evaluation of 
the microrod system from an isolated to an open and dynamic system. As a consequence the 
natural clearance mechanism of the lung had to be taken into account. Upon particle 
engulfment macrophages can migrate from the respiratory tract into the direction of the 
pharynx in order to get swallowed for host protection.[12] So before the study it was not 
predictable if enough macrophages would reside within the lungs for a time frame of up to 9 
days to actually allow us to measure luciferase activity. This point was in particular important 
since in the in vitro setting higher luciferase expression was observed for a longer residence 
time of the rods in the cells. But in contrast to the preliminary thoughts, residential 
macrophages were present in the lungs at every evaluated time point, carrying particles and 
expressing luciferase. This observation was vital for the initial working hypothesis to design a 
carrier for the engineering of alveolar macrophages, which stay in the respiratory system 
influencing their microenvironment due to the genetic modifications provided by the particles. 
Therefore the particles were successfully shown to be an efficient delivery vehicle for the 
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implementation of genetic material, which can be easily translated from cell culture to in vivo 
environments.   
 
  
 
 
 
 
 
0
50000
100000
150000
200000
250000
300000
P
.1
P
.2
P
.3
P
.4
P
.5
P
.6
P
.7
P
.8
P
.9
P
.1
0
 4
.1
 4
.2
 4
.3
 4
.4
 4
.5
 4
.6
 4
.7
 4
.8
 4
.9
 4
.1
0
 7
.1
 7
.2
 7
.3
 7
.4
 7
.5
 7
.6
 7
.7
 7
.8
 7
.9
 7
.1
0
 9
.1
 9
.2
 9
.3
 9
.4
 9
.5
 9
.6
 9
.7
 9
.8
 9
.9
 9
.1
0
B
io
lu
m
in
e
sc
e
n
ce
 [
R
LU
 /
 m
g 
p
ro
te
in
] 
Luciferase Transfection Assay - BALB/c Macrophages  
Figure 4: Results of the luciferase assay for alveolar macrophages from BALB/c mice. Values of the x-axis are given in 
double digits referring to the evaluated time point in days for the first digit. For every time point 10 individual animals are 
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Summary and Outlook 
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Since decades gene therapy is one of the greatest promises held by biomedical research. 
Potentially adaptable to a wide range of individual conditions and clinical pictures of patients, 
it offers, in theory, a nearly unlimited toolbox to treat diseases at its origin. Although there are 
only few market products available, gene therapy is still regarded as a powerful tool, which 
needs further improvement to exploit its full potential.  
In order to contribute to this development, a novel pulmonary delivery system for genetic 
material was presented in this work. Therefore, the objective of the thesis was the adaptation 
of a previously introduced particle preparation technique to the needs of successful transport 
of genes into a target cell of therapeutic relevance. Based on a bottom-up engineering 
approach, nanoparticles were connected with each other within the pores of a shape-defining 
template membrane. According to the aspherical, cylindrical shape of the pores, the resulting 
nanostructured microparticles were successfully formed into a rod-like geometry. The micron 
architecture was stabilized by a Layer-by-Layer coating procedure, which turned out to be 
very flexible and robust to changes in excipients allowing the use of different 
polyelectrolytes. Both non-biodegradable and biodegradable excipients were applied for 
stabilization offering the freedom to choose the most suitable agents depending on the desired 
target cell line.  
Two analytical methods were identified, which could be applied as in-process controls during 
fabrication. Ethidium bromide-loaded agarose gels were a viable tool to visualize the progress 
of the stabilization also giving information about the efficient condensation of the DNA onto 
the surface of the particles as well as for the protection by the buffering agent. Applying ICP-
OES as a cargo quantification tool provides the fast determination of excipients consuming 
only low amounts of particles. Therefore, the method can be used as a standard analytical tool 
for every particle batch prior to application. The particle dimensions were chosen according to 
the pulmonary application route showing an MMAD of 2.57 µm. This indicates the particles 
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to be able to reach the deep lung. The fine particle fraction of 12 % is quite low in comparison 
to market products highlighting a need for further optimization. This could potentially be 
achieved by an efficient method to reduce residual moisture in the foremost hygroscopic 
formulation.  
In terms of the functionality of the microrod system, it was shown to be efficient in 
implementing the transported model gene into alveolar macrophages for in vitro and in vivo 
environments. In both cases, the particles were well tolerated and no toxic effects could be 
observed. Overall, it can be stated that all main hurdles during the development of the 
presented system could be overcome. Starting with the first DNA-stabilized microrods and the 
application of suitable physicochemical and administration-related characterization methods, 
the project was advanced to a successful application in the target cells. Here, we could show 
our particles to be superior to a commercial transfection agent in terms of prolonged gene 
expression. Building on this data, an animal study was conducted showing the microrods to be 
easy to translate from cell culture to in vivo environments.  
Furthermore, for the first time the dependency of gene expression in murine alveolar 
macrophages on the LbL design could be shown. As presented in the first transfection 
experiment, microrods stabilized by the least number of double-layers showed higher 
luciferase expression within the observed time frame of the study. A clear trend was observed 
in comparison to higher layer numbers due to the increasing electrostatically driven stability 
of the carrier system, which sustained plasmid-DNA release. In addition to cargo loading, also 
the position of the plasmid was found to have a strong impact on transfection. Whereas 
pCMV-luc in the outermost layer got degraded under harsh acidic and enzymatic conditions 
in phagolysosomes, a successful gene delivery from inner layers was demonstrated. These 
new insights into macrophage transfection can contribute to the controlled and prolonged 
expression of transported genes for therapeutic purposes.  
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Regarded as a platform technology, the introduced methods have the potential to pave the way 
for more specialized and therefore therapeutically relevant applications. Especially by 
addressing altered gene expression of macrophages, which is assumed to promote diseases 
within the respiratory tract, microrods are a promising tool to evaluate the impact of 
therapeutic nucleic acid-based drugs, including RNAs, such as siRNAs or miRNAs. 
Furthermore, the applied nanoparticulates can be exploited to not only provide a moldable 
material. Drug-loaded nanoparticles enable combination therapies potentially improving the 
therapeutic performance of the microrod system. In this context, a switch from silica to 
biodegradable compounds, such as calcium phosphate, could be viable, but also organic 
polymers, e.g. PLGA can be used. For future experiments including extended in vitro and in 
vivo setups large amounts of rods are needed indicating a need of scalability of the method. A 
cost-efficient yield optimization to the gram scale is desired and also currently under 
investigation.    
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AFM Atomic Force Microscopy 
ALF Artificial Lysosomal Fluid 
AR Aspect Ratio 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
bPEI branched Polyethyleneimine 
C Carbon 
CHT Chitosan 
ConA Convavalin A 
DANN Desoxyribonucleic acid 
DAPI (4',6-diamidino-2-phenylindole) 
DCM Dichloromethane 
DEAE-Dex Diethylaminoethyl Dextran  
DexS Dextran sulfate 
DL Double-Layer 
DMSO Dimethyl sulfoxide 
DPI Dry Powder Inhaler 
EDTA Ethylenediaminetetraacetic acid 
EMA European Medicine Agency 
EPR Enhanced Permeability and Retention 
EtBr Ethidium bromide 
FDA Food and Drug Administration 
FPF Fine Particle Fraction 
GFP Green Fluorescent Protein 
H Hydrogen 
HES Hydroxyethyl starch 
ICP-OES Iductively Coupled Plasma – Optical Emission Spectroscopy 
IFN Interferon gamma 
IL Interleukine 
ITC Isothermal Titration Calorimetry 
LbL Layer-by-Layer 
MDI Metered Dose Inhaler 
Mg Magnesium 
MMAD Mass Median Aerodynamic Diameter 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N Nitrogen 
NSAID Non-steroidal, Anti-inflammatory Drug 
pCMV-luc Plasmid DNA, CMV-Promotor, encoding for Luciferase 
PE- Polyanion 
PE+ Polycation 
SEM Scanning Electron Microscopy 
SNP Silica Nanoparticles 
TAM Tumor-associated Macrophage 
TEM Transmission Electron Microscopy 
THF Tetrahydrofuran 
TNF Tumor Necrosis Factor 
TRIS Tris(hydroxymethyl)aminomethane 
 
 - 120 - 
 
Acknowledgements 
 
First and foremost, I want to express my deepest gratitude to my doctoral father Prof. Dr. 
Marc Schneider for making me a member of his research group. I would like to thank him for 
creating a working environment based on trust and appreciation, which made the last years a 
real joy. His continuous support and inspirational scientific contributions were substantial 
factors to advance a fascinating field of research.  
I want to thank Prof. Dr. Claus-Michael Lehr for his expert opinion on the thesis and many 
fruitful discussions during joint meetings with his drug delivery division at the HIPS. In this 
regard I want to highlight Remi and her positive attitude as a kind gift from the Netherlands. 
As my first scientific supervisor always said, it’s all about people. In this regard I want to 
thank all my cooperation partners. Prof. Dr. Udo Bakowsky and Shashank Reddy 
Pinnapireddy from the Institute of Pharmaceutical Technology and Biopharmaceutics at 
Marburg University made essential contributions to the thesis carrying out all in vitro assays. 
Thank you, Shashank for your tremendous work and constant efforts to make this thing work. 
I always appreciated your relaxed and positive attitude as well as your operational skills at the 
bench.  
Animal studies would have not been possible without the help of Prof. Dr. Thomas Tschernig 
and Bodo Wonnenberg from the Medical Faculty of Saarland University. Thank you, Thomas 
and Bodo for the interesting discussions and insights into lung physiology and medical 
research.  
I want to thank all my colleagues from Marburg and Saarbrücken for a great time. Here, I 
especially want to address Matthias and Boris, which are outstanding personalities and it was 
a blast for me spending a year with you in Marburg. I want to thank my colleagues Clemens, 
Saeed, Chen, Agnes, Afra, Joschi, Caro, Sarah, Nesma and Baseer for so many social events 
 - 121 - 
 
making Schneider Lab a second family. In this context I want to highlight Marcel and Daniel. 
Thank you Marciboy for your clever ideas and design skills, burger sessions and trash talk. 
Stay the kind and helpful swaggy teddy bear that you are. Thank you Daniel for your 
analytical, political and nerdy mind, which led to so many hilarious discussions; simply an 
essential part of my PhD time.  
I would also like to thank the staff from Schneider Lab Isabelle, Peter and especially Marijas, 
who spent many hours in the dark caves of the cell culture for my project. 
I want to address my interns Johannes Büscher, Alexander König and Felicia Hartmann, who 
did a great job during their time in my lab. Thank you Feli for your ambition and appreciative 
support, for your constant encouragement and your love.       
I deeply thank my siblings and parents Daniela, Alexander, Dorothea and Jürgen for all your 
support for the path I chose.   
 
 
 
 
 
 
 
 
 
 - 122 - 
 
 
 
 
 
 
Personal 
Information 
 
 
 
 
 
 
Doctoral 
Thesis 
 
04/14 – 03/17 
 
 
 
 
Professional 
Training 
 
05/13 – 10/13 
 
 
11/12 – 04/13  
 
Curriculum Vitae  
 
 
 
 
 
Michael Möhwald  
Date of Birth: September 26th, 1986 in Heidelberg 
Nationality: German 
Contact:  michael.moehwald@gmx.de   
 
 
 
 
 
Institute of Biopharmaceutics and Pharmaceutical Technology,                                   
Department of Pharmacy, Saarland University, Saarbrücken 
Group of Prof. Dr. Marc Schneider  
 
 
 
 
 
Pharmaceutical Training in the Division Formulation Sciences –  New 
Biological Entities at AbbVie Germany, Ludwigshafen  
 
Pharmaceutical Training at St. Ulrich Apotheke, Östringen 
 
 - 123 - 
 
 
03/11 – 05/11  
 
 
 
02/08 – 09/08 
 
 
Vocational  
Training   
                                                           
04/14 – 03/17      
 
 
 
Educational 
Background 
 
01/14 
 
10/07 – 10/12        
 
 
10/06 – 09/07     
 
07/97 – 07/06   
Assistant Scientist, Pharmaceutical Technology and Biopharmaceutics, Group 
of Prof. Dr. Gerhard Winter, LMU München 
 
 
Assistant Scientist, Pharmaceutical Biology-Biotechnology, Group of Prof. Dr. 
Ernst Wagner, LMU München 
 
 
 
 
 
Advanced Curriculum in Pharmaceutical Technology  
“Fachapotheker für Pharmazeutische Technologie” 
      
 
 
 
 
Licensed Pharmacist (Approbation) 
 
Pharmaceutical Studies at Ludwig-Maximilians-Universität  
München 
  
Medical Studies at Ruprecht-Karls-Universität Heidelberg    
 
Abitur at Leibniz-Gymnasium Östringen 
  
 
